<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id>
<journal-title>Frontiers in Psychiatry</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Psychiatry</abbrev-journal-title>
<issn pub-type="epub">1664-0640</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fpsyt.2013.00002</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Psychiatry</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Elevated Expression of Serotonin 5-HT<sub>2A</sub> Receptors in the Rat Ventral Tegmental Area Enhances Vulnerability to the Behavioral Effects of Cocaine</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Herin</surname> <given-names>David V.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn003"><sup>&#x02021;</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bubar</surname> <given-names>Marcy J.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Seitz</surname> <given-names>Patricia K.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Thomas</surname> <given-names>Mary L.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn002"><sup>&#x02020;</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hillman</surname> <given-names>Gilbert R.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tarasenko</surname> <given-names>Yevgeniya I.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wu</surname> <given-names>Ping</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Cunningham</surname> <given-names>Kathryn A.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="author-notes" rid="fn001">&#x0002A;</xref>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Center for Addiction Research, University of Texas Medical Branch</institution> <country>Galveston, TX, USA</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Pharmacology and Toxicology, University of Texas Medical Branch</institution> <country>Galveston, TX, USA</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Neuroscience and Cell Biology, University of Texas Medical Branch</institution> <country>Galveston, TX, USA</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: F. G. Moeller, University of Texas Health Science Center at Houston, USA</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Therese A. Kosten, Baylor College of Medicine, USA; Mehmet Sofuoglu, VA Connecticut Healthcare System, USA</p></fn>
<fn fn-type="corresp" id="fn001"><p>&#x0002A;Correspondence: Kathryn A. Cunningham, Department of Pharmacology and Toxicology, Center for Addiction Research, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-0615, USA. e-mail: <email>kcunning&#x00040;utmb.edu</email></p></fn>
<fn fn-type="present-address" id="fn002"><p><sup>&#x02020;</sup>Current address: Mary L. Thomas, Department of Pharmacology, Ross University, North Brunswick, NJ, USA.</p></fn>
<fn fn-type="other" id="fn003"><p><sup>&#x02021;</sup>David V. Herin author deceased</p></fn>
<fn fn-type="other" id="fn004"><p>This article was submitted to Frontiers in Addictive Disorders and Behavioral Dyscontrol, a specialty of Frontiers in Psychiatry.</p></fn>
</author-notes>
<pub-date pub-type="epreprint">
<day>30</day>
<month>11</month>
<year>2012</year>
</pub-date>
<pub-date pub-type="epub">
<day>06</day>
<month>02</month>
<year>2013</year>
</pub-date>
<pub-date pub-type="collection">
<year>2013</year>
</pub-date>
<volume>4</volume>
<elocation-id>2</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>11</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>01</month>
<year>2013</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2013 Herin, Bubar, Seitz, Thomas, Hillman, Tarasenko, Wu and Cunningham.</copyright-statement>
<copyright-year>2013</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.</p></license>
</permissions>
<abstract>
<p>The dopamine mesocorticoaccumbens pathway which originates in the ventral tegmental area (VTA) and projects to the nucleus accumbens and prefrontal cortex is a circuit important in mediating the actions of psychostimulants. The function of this circuit is modulated by the actions of serotonin (5-HT) at 5-HT<sub>2A</sub> receptors (5-HT<sub>2A</sub>R) localized to the VTA. In the present study, we tested the hypothesis that virally mediated overexpression of 5-HT<sub>2A</sub>R in the VTA would increase cocaine-evoked locomotor activity in the absence of alterations in basal locomotor activity. A plasmid containing the gene for the 5-HT<sub>2A</sub>R linked to a synthetic marker peptide (Flag) was created and the construct was packaged in an adeno-associated virus vector (rAAV-5-HT<sub>2A</sub>R-Flag). This viral vector (2&#x02009;&#x003BC;l; 10<sup>9&#x02013;10</sup> transducing units/ml) was unilaterally infused into the VTA of male rats, while control animals received an intra-VTA infusion of Ringer&#x02019;s solution. Virus-pretreated rats exhibited normal spontaneous locomotor activity measured in a modified open-field apparatus at 7, 14, and 21&#x02009;days following infusion. After an injection of cocaine (15&#x02009;mg/kg, ip), both horizontal hyperactivity and rearing were significantly enhanced in virus-treated rats (<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05). Immunohistochemical analysis confirmed expression of Flag and overexpression of the 5-HT<sub>2A</sub>R protein. These data indicate that the vulnerability of adult male rats to hyperactivity induced by cocaine is enhanced following increased levels of expression of the 5-HT<sub>2A</sub>R in the VTA and suggest that the 5-HT<sub>2A</sub>R receptor in the VTA plays a role in regulation of responsiveness to cocaine.</p>
</abstract>
<kwd-group>
<kwd>5-HT<sub>2A</sub> receptor</kwd>
<kwd>cocaine</kwd>
<kwd>serotonin</kwd>
<kwd>virally mediated gene transfer</kwd>
<kwd>AAV</kwd>
<kwd>ventral tegmental area</kwd>
<kwd>locomotor activity</kwd>
<kwd>psychostimulants</kwd>
</kwd-group>
<counts>
<fig-count count="4"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="91"/>
<page-count count="12"/>
<word-count count="10496"/>
</counts>
</article-meta>
</front>
<body>
<sec sec-type="introduction">
<title>Introduction</title>
<p>Cocaine addiction is marked by significant morbidity and loss of human potential, yet consistently effective and accessible recovery options remain limited. This fact underscores the continuing need to uncover the neural factors that drive vulnerability to cocaine addiction and relapse and to establish new pharmacological strategies to halt or reverse the progression of the disorder. Cocaine inhibits reuptake of monoamines, including dopamine (DA) and serotonin (5-hydroxytryptamine; 5-HT; Koe, <xref ref-type="bibr" rid="B50">1976</xref>) and the enhanced efflux of DA within the mesocorticoaccumbens circuit is critical in the generation of cocaine-evoked behaviors (Kelly and Iversen, <xref ref-type="bibr" rid="B49">1976</xref>; Delfs et al., <xref ref-type="bibr" rid="B27">1990</xref>; Callahan et al., <xref ref-type="bibr" rid="B17">1994</xref>). The mesocorticoaccumbens DA neurons, which originate in the ventral tegmental area (VTA) and project prominently to subcortical [e.g., nucleus accumbens (NAc)] and cortical structures [e.g., prefrontal cortex (PFC)], are under the modulatory control of the 5-HT system (Alex and Pehek, <xref ref-type="bibr" rid="B1">2007</xref>), with 5-HT neurons in the dorsal raphe nucleus innervating both cell body and terminal regions of the mesocorticoaccumbens circuit (Halliday and Tork, <xref ref-type="bibr" rid="B39">1989</xref>). As such, the 5-HT system is also an important mediator of cocaine-evoked behaviors (for reviews, see Walsh and Cunningham, <xref ref-type="bibr" rid="B85">1997</xref>; Muller and Huston, <xref ref-type="bibr" rid="B63">2006</xref>; Bubar and Cunningham, <xref ref-type="bibr" rid="B13">2008</xref>; Filip et al., <xref ref-type="bibr" rid="B32">2010</xref>).</p>
<p>The 5-HT<sub>2A</sub> receptor (5-HT<sub>2A</sub>R), one of 14 subtypes of 5-HT receptors (Hoyer et al., <xref ref-type="bibr" rid="B43">2002</xref>), plays an integral role in mediating the serotonergic influence upon cocaine-evoked behaviors (Muller and Huston, <xref ref-type="bibr" rid="B63">2006</xref>; Bubar and Cunningham, <xref ref-type="bibr" rid="B13">2008</xref>). Blockade of the 5-HT<sub>2A</sub>R with a selective antagonist (e.g., M100907; SR46349B) significantly reduces cocaine-evoked hypermotility (O&#x02019;Neill et al., <xref ref-type="bibr" rid="B68">1999</xref>; McMahon and Cunningham, <xref ref-type="bibr" rid="B59">2001</xref>; Fletcher et al., <xref ref-type="bibr" rid="B36">2002</xref>; Filip et al., <xref ref-type="bibr" rid="B33">2004</xref>; Szucs et al., <xref ref-type="bibr" rid="B84">2005</xref>), behavioral sensitization (Filip et al., <xref ref-type="bibr" rid="B33">2004</xref>; Zayara et al., <xref ref-type="bibr" rid="B91">2011</xref>), and behavioral disinhibition (Anastasio et al., <xref ref-type="bibr" rid="B4">2011</xref>; Fletcher et al., <xref ref-type="bibr" rid="B37">2011</xref>; Cunningham et al., <xref ref-type="bibr" rid="B24">2013</xref>), as well as the discriminative stimulus effects of cocaine (Filip et al., <xref ref-type="bibr" rid="B34">2006</xref>) and cocaine- (Fletcher et al., <xref ref-type="bibr" rid="B36">2002</xref>) and cue-primed (Nic Dhonnchadha et al., <xref ref-type="bibr" rid="B65">2009</xref>; Pockros et al., <xref ref-type="bibr" rid="B74">2011</xref>) reinstatement of cocaine-seeking in rats. Systemic administration of the non-selective 5-HT<sub>2A</sub>R antagonist ketanserin inhibited cocaine-evoked hypermotility simultaneous with inhibition of cocaine-evoked DA release in the NAc (Broderick et al., <xref ref-type="bibr" rid="B10">2004</xref>), suggesting an important role for 5-HT<sub>2A</sub>R-modulation of DA mesocorticoaccumbens neurotransmission in cocaine-evoked behaviors mediated by this circuit.</p>
<p>The 5-HT<sub>2A</sub>R is a G protein-coupled receptor (Berg et al., <xref ref-type="bibr" rid="B6">1994</xref>) expressed throughout the nodes of the mesocorticoaccumbens circuit (Cornea-Hebert et al., <xref ref-type="bibr" rid="B21">1999</xref>; Doherty and Pickel, <xref ref-type="bibr" rid="B29">2000</xref>; Xu and Pandey, <xref ref-type="bibr" rid="B89">2000</xref>; Nocjar et al., <xref ref-type="bibr" rid="B66">2002</xref>; Miner et al., <xref ref-type="bibr" rid="B61">2003</xref>). The 5-HT<sub>2A</sub>R resident in the VTA is localized to both DA and non-DAergic [presumably &#x003B3;-aminobutyric (GABA) or glutamate] neurons within the VTA (Doherty and Pickel, <xref ref-type="bibr" rid="B29">2000</xref>; Nocjar et al., <xref ref-type="bibr" rid="B66">2002</xref>), and appear to be integral in modulating psychostimulant-induced behaviors mediated by the mesocorticoaccumbens circuit. Microinfusion of the selective 5-HT<sub>2A</sub>R antagonist M100907 into the VTA, but not the NAc, attenuated hyperactivity evoked by systemic administration of cocaine at doses that did not alter basal motor activation (McMahon et al., <xref ref-type="bibr" rid="B60">2001</xref>). Likewise, intra-VTA 5-HT<sub>2A</sub>R antagonist administration significantly blocked amphetamine-evoked hyperactivity and associated DA release in the NAc, with no effect upon basal motor activity or DA efflux in NAc (Auclair et al., <xref ref-type="bibr" rid="B5">2004</xref>). We have observed that microinfusion of the preferential 5-HT<sub>2A</sub>R agonist 1-(2,5-dimethoxy-4-iodo)-2-aminopropane (DOI) alone into the VTA is sufficient to evoke hyperactivity in rats (Herin et al., unpublished observations). Thus, activation of 5-HT<sub>2A</sub>R resident in the VTA results in behaviorally significant outcomes, and likewise appears to play a critical role in cocaine-evoked behaviors mediated by the DA mesocorticoaccumbens circuit.</p>
<p>The virally mediated gene transfer technique represents a targeted means to manipulate the expression of important proteins in the brains of adult animals (Carlezon et al., <xref ref-type="bibr" rid="B18">1997</xref>; Bolanos et al., <xref ref-type="bibr" rid="B8">2003</xref>; Edry et al., <xref ref-type="bibr" rid="B30">2011</xref>). A recombinant adeno-associated virus (rAAV) can be used to selectively transduce neurons for a long duration (weeks to months) with a minimum of toxicity and inflammation (McCown et al., <xref ref-type="bibr" rid="B57">1996</xref>; Lo et al., <xref ref-type="bibr" rid="B56">1999</xref>). In the present study, we have exploited rAAV-mediated gene transfer to investigate whether overexpression of the 5-HT<sub>2A</sub>R in the VTA alters the vulnerability of adult male rats to the hypermotive effects of cocaine. We developed an rAAV containing the coding region for the 5-HT<sub>2A</sub>R linked to a synthetic marker peptide (Flag; rAAV-5-HT<sub>2A</sub>R-Flag), and infused vehicle or rAAV-5-HT<sub>2A</sub>R-Flag unilaterally into the VTA of experimental animals, followed by measurement of basal and cocaine-evoked hyperactivity. Immunohistochemical analyses were used to confirm 5-HT<sub>2A</sub>R overexpression as well as expression of the Flag peptide.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and Methods</title>
<sec>
<title>Animals</title>
<p>Male Sprague-Dawley rats (Harlan Sprague-Dawley, Inc., Indianapolis, IN, USA) weighed 250&#x02013;275&#x02009;g at the beginning of the study. The rats were housed (initially four/cage) in standard plastic rodent cages in a temperature (21&#x02013;23&#x000B0;C) and humidity (55&#x02013;65%) controlled environment under a 12-h light/dark cycle (lights on 07:00&#x02009;h). Animals were acclimated to the colony for 3&#x02013;5&#x02009;days prior to surgery, after which they were single-housed and allowed to recover for at least one week prior to the start of experimental sessions. All animals were provided with food and water <italic>ad libitum</italic>. Experiments were conducted during the light phase of the light-dark cycle (1200&#x02013;1800&#x02009;h) and were in accordance with the National Institutes of Health <italic>Guide for the Care and Use of Laboratory Animals</italic> and with approval from the UTMB Institutional Animal Care and Use Committee.</p>
</sec>
<sec>
<title>Viral vectors</title>
<p>The cDNA containing the coding region for the rat 5-HT<sub>2A</sub>R was obtained (Dr. J. Liu, University of Cincinnati). Primers were designed to amplify only the coding region of the 5-HT<sub>2A</sub>R and to add a <italic>Bam</italic>HI site (to the 5&#x02032; end), <italic>Spe</italic>I site (to the 3&#x02032; end), 24 bases coding for a synthetic marker (Flag) protein and a stop codon. PCR amplification was performed using an rTtH-XL polymerase (Perkin Elmer, Boston, MA, USA) and the product (5-HT<sub>2A</sub>R-Flag) was purified by preparative agarose gel electrophoresis followed by dialysis, phenol/chloroform/isoamyl alcohol (25:24:1) extraction and ethanol precipitation.</p>
<p>The 5-HT<sub>2A</sub>R-Flag DNA was then ligated into a pCW plasmid, which is appropriate for viral packaging. The pCW plasmid (provided by Dr. D. J. Poulsen; University of Montana) contains the inverted terminal repeats (ITR) of AAV, a chick &#x003B2;-actin (CAG) promoter, multiple cloning sites, and a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE; Stone et al., <xref ref-type="bibr" rid="B82">2005</xref>). 5-HT<sub>2A</sub>R-Flag (300&#x02009;fmol) and pCW (30&#x02009;fmol) were digested with <italic>Bam</italic>HI (2 units) and <italic>Spe</italic>I (5 units) for 2&#x02009;h at 37&#x000B0;C. Ligation was performed with a kit (TaKaRa Biochemical, Inc., Berkeley, CA, USA). Ten microliters of the resultant cDNA was used to transform DH5-&#x003B1; ultracompetent <italic>E. coli</italic> containing 50&#x02009;&#x003BC;g/ml ampicillin. Plasmid DNA was isolated from 20 colonies and tested for inclusion of the plasmid by digestion with <italic>Bam</italic>HI and <italic>Spe</italic>I. One positive colony was CsCl-purified and sequenced at the UTMB Molecular Biology Core Facility. Functionality of the transgene was determined by transfection in raphe RN46A cells (provided by Dr. Scott Whittemore, University of Miami; White et al., <xref ref-type="bibr" rid="B86">1994</xref>) followed by immunocytochemical detection with 5-HT<sub>2A</sub>R and Flag antibodies.</p>
<p>The rAAV-5-HT<sub>2A</sub>R-Flag was prepared by cotransfecting three plasmids into human embryonic kidney cells (HEK 293 cell line) based on previous protocols (Xiao et al., <xref ref-type="bibr" rid="B88">1998</xref>; Wu et al., <xref ref-type="bibr" rid="B87">2002</xref>) utilizing an AAV helper plasmid (pXX2) and an adenovirus helper plasmid (pXX6). The HEK cells were cultured in 150&#x02009;mm dishes containing DMEM/10% FBS at 37&#x000B0;C, 5% CO<sub>2</sub>. When cells reached 80% confluence, calcium phosphate precipitation was used for co-transfection with pCW-5-HT<sub>2A</sub>R-Flag, pXX2, and pXX6. Following a brief rinse with DMEM, OptiMEM (Life Technologies)/10% FBS/120&#x02009;&#x003BC;M chloroquine was added to the cells. Then 2.5&#x02009;ml of DNA&#x02013;calcium phosphate solution was added per plate. This solution contained three plasmids at the molar ratio of 7:2:4, 125&#x02009;mM CaCl<sub>2</sub> and 1&#x000D7; HBS (2.5&#x02009;M NaCl, 0.25&#x02009;M HEPES, 75&#x02009;mM Na<sub>2</sub>HPO<sub>4</sub>, pH 7.1). Cells were cultured with 5% CO<sub>2</sub> at 37&#x000B0;C for 18&#x02009;h, and changed with OptiMEM/10% FBS. Two days after co-transfection, cells and medium were collected, centrifuged at 1140&#x02009;<italic>g</italic> for 15&#x02009;min, and then resuspended in 150&#x02009;mM NaCl/20&#x02009;mM Tris pH 8.0 at 5&#x02009;&#x000D7;&#x02009;10<sup>6</sup>&#x02009;cells/ml. The cell suspension was further treated with 0.54% deoxycholate (Sigma, St. Louis, MO, USA) and 50&#x02009;U/ml Benxonase (Sigma) at 37&#x000B0;C for 1&#x02009;h. Following centrifugation at 3000&#x02009;<italic>g</italic> at room temperature for 20&#x02009;min, supernatants were subjected to a cycle of freeze &#x02212; thaw, and then centrifuged again at 10,000&#x02009;<italic>g</italic> at 4&#x000B0;C for 30&#x02009;min. The supernatant was collected, filtered through a 1-&#x003BC;m disk filter (Fisher, Pittsburgh, PA, USA), and then run by gravity through a heparin agarose type I column (Sigma) pre-equilibrated with phosphate buffer saline/1&#x02009;mM MgCl<sub>2</sub>/2.5&#x02009;mM KCl phosphate-buffered saline (PBS-MK). After four washes with 5&#x02009;ml PBS-MK each, rAAV viruses were eluted by 9&#x02009;ml of 1&#x02009;M NaCl/PBS-MK. The first 2&#x02009;ml was discarded. The next 7&#x02009;ml was collected, desalted by running through a Centricon Plus-20/Biomax-100 (Fisher) with four changes of lactated Ringer&#x02019;s solution, then concentrated by centrifugation at 3000&#x02009;<italic>g</italic> at room temperature, and the elution was collected. Dot blot indicated that the titer of the packaged virus was in the range of 10<sup>9</sup>&#x02013;10<sup>10</sup> transducing units/ml.</p>
</sec>
<sec>
<title>Animal surgery</title>
<p>Rats (<italic>n</italic>&#x02009;&#x0003D;&#x02009;10/group) were anesthetized intramuscularly (IM) with 43&#x02009;mg/kg of ketamine, 8.6&#x02009;mg/kg of xylazine, and 1.5&#x02009;mg/kg of acepromazine in physiological saline (0.9% NaCl) and placed in a Kopf rat stereotaxic apparatus (David Kopf Instruments, Tujunga, CA, USA) with the upper incisor bar at &#x02212;3.8&#x02009;mm below the interaural line. A Hamilton microsyringe (Hamilton, Reno, NV, USA) was then lowered unilaterally into the VTA at a 9&#x000B0; from the midsaggital plane in relation to bregma: [anteroposterior (AP) &#x02212;5.3&#x02009;mm, mediolateral (ML)&#x02009;&#x0002B;&#x02009;1.3&#x02009;mm, and dorsoventral (DV) &#x02212;8.1 and 8.5&#x02009;mm from skull (Paxinos and Watson, <xref ref-type="bibr" rid="B69">1998</xref>; McMahon et al., <xref ref-type="bibr" rid="B60">2001</xref>; Shank et al., <xref ref-type="bibr" rid="B80">2007</xref>)]. The rAAV-5-HT<sub>2A</sub>R-Flag (2&#x02009;&#x003BC;l, 10<sup>9</sup>&#x02013;10<sup>10</sup> transducing units/ml) or lactated ringer&#x02019;s solution vehicle control (2&#x02009;&#x003BC;l) was infused into the VTA (<italic>n</italic>&#x02009;&#x0003D;&#x02009;10 per group) using the UMP II infusion pump (WPI, Sarasota, FL, USA) at a rate of 18&#x02009;nl/min; the infusion lasted 2&#x02009;h. Following infusion, the needle was left in place for 10&#x02009;min followed by withdrawal from the brain and wound closure. Rats received a single injection (IM) of 300,000&#x02009;U of sodium ampicillin after surgery and were allowed 1&#x02009;week to recover, during which time they were handled and weighed daily.</p>
</sec>
<sec>
<title>Behavioral procedures</title>
<sec>
<title>Apparatus</title>
<p>Locomotor activity was quantified using a modified open-field activity system under low-light conditions (San Diego Instruments, San Diego, CA, USA). Each enclosure consisted of a clear Plexiglas open-field (40&#x02009;cm&#x02009;&#x000D7;&#x02009;40&#x02009;cm&#x02009;&#x000D7;&#x02009;40&#x02009;cm) and a 4&#x02009;&#x000D7;&#x02009;4 photobeam matrix located 4&#x02009;cm above the cage floor for the measurement of horizontal activity; each monitor was housed within sound-attenuating chambers. A second horizontal row of 16 photobeams located 16&#x02009;cm from the floor allowed the measurement of rearing. Activity counts were made by the control software (Photobeam Activity Software, San Diego Instruments, San Diego, CA, USA) and stored for statistical evaluation. Video cameras located above the enclosures were used to monitor activity continuously without disruption of behavior.</p>
</sec>
<sec>
<title>Effects of 5-HT<sub>2A</sub>R overexpression on basal and cocaine-evoked locomotor activity</title>
<p>On Day 7 following surgery, animals were placed in activity monitors and horizontal activity and rearing were recorded for 60&#x02009;min, followed by return to the animal colony. Additionally, activity was again measured in these same animals on Days 14 and 21 following surgery for 60&#x02009;min on each day. On Day 21, following the measurement of basal locomotor activity, all animals were challenged with 15&#x02009;mg/kg of cocaine [(-)-cocaine HCl salt; National Institute on Drug Abuse, Research Triangle, NC, USA dissolved in 0.9% NaCl], a dose that consistently produces hyperactivity in our laboratory (McCreary and Cunningham, <xref ref-type="bibr" rid="B58">1999</xref>; De La Garza and Cunningham, <xref ref-type="bibr" rid="B26">2000</xref>; Liu and Cunningham, <xref ref-type="bibr" rid="B55">2006</xref>; Cunningham et al., <xref ref-type="bibr" rid="B24">2013</xref>). Immediately following injection, horizontal activity and rearing were measured for 60&#x02009;min.</p>
<p>Both horizontal activity and rearing counts were totaled for each animal in 10-min time bins and across the 60-min test sessions. All data are presented as mean horizontal activity counts or rearing counts (&#x000B1;SEM). For basal locomotor activity, a two-way ANOVA was used to analyze the effects of intra-VTA pretreatment (control or rAAV-5-HT<sub>2A</sub>R-Flag; factor 1) and day (Days 7, 14, 21; factor 2) with pretreatment as a between-subjects factor and day as a within-subjects factor. Planned comparisons for each test day were made with a Student&#x02019;s <italic>t</italic>-test with a Bonferroni correction. To analyze the time course of cocaine-evoked activity on Day 21, a two-way ANOVA with factors of intra-VTA pretreatment (between-subjects) and time (within-subjects) was utilized followed by planned comparisons at each time point using a Student&#x02019;s <italic>t</italic>-test with a Bonferroni correction. Differences in the mean total hyperactivity observed for the 60-min period following cocaine injection on Day 21 were analyzed with a Student&#x02019;s <italic>t</italic>-test. All statistical tests were determined using SAS for Windows (Version 8.1) with an experiment wise &#x003B1;&#x02009;&#x0003D;&#x02009;0.05.</p>
</sec>
<sec>
<title>Histology and transgene detection</title>
<p>At the end of behavioral testing on Day 21, animals were deeply anesthetized with an intraperitoneal (IP) injection of pentobarbital (Sigma, 100&#x02009;mg/kg) and transcardially perfused with PBS followed by 3% buffered paraformaldehyde. Brains were then removed, blocked at the mid-pons, and post-fixed in paraformaldehyde at room temperature for 2&#x02009;h. Tissue was then cryoprotected in 30% sucrose solution at 4&#x000B0;C for 48&#x02009;h. Brains were frozen with crushed dry ice and stored at &#x02212;80&#x000B0;C. Coronal sections (50&#x02009;&#x003BC;m) were prepared with a Leica cryostat (CM 1850) at &#x02212;20&#x000B0;C and processed to verify microinjection placement and transgene expression using immunohistochemistry (see below). Data obtained from rats with infusion sites outside of the VTA were excluded from analysis.</p>
<p>To validate the ability of the rAAV construct to establish expression of 5-HT<sub>2A</sub>R and Flag within the VTA, we employed immunohistochemical techniques using diaminobenzidine detection and light microscopy as described previously (Allen and MacPhail, <xref ref-type="bibr" rid="B2">1991</xref>; Ross et al., <xref ref-type="bibr" rid="B76">2006</xref>; Shank et al., <xref ref-type="bibr" rid="B80">2007</xref>). Briefly, sections were blocked with a solution containing 1.5% normal goat serum (Vector Laboratories, Burlingame, CA, USA) in PBS with 0.4% Triton-X (PBS-T; Sigma), followed by incubation in PBS-T containing a polyclonal antibody for either the 5-HT<sub>2A</sub>R (1:1000; courtesy of Dr. Bryan Roth, Case Western University Cleveland, OH, USA; Garlow et al., <xref ref-type="bibr" rid="B38">1993</xref>; Roth et al., <xref ref-type="bibr" rid="B77">1995</xref>; Cornea-Hebert et al., <xref ref-type="bibr" rid="B22">2002</xref>; Nocjar et al., <xref ref-type="bibr" rid="B66">2002</xref>; Bubar et al., <xref ref-type="bibr" rid="B15">2005</xref>; Ross et al., <xref ref-type="bibr" rid="B76">2006</xref>) or Flag peptide (1:1000; Sigma). Sections were washed in PBS, incubated in PBS-T containing biotinylated goat-anti-rabbit IGg (1:400; Vector), incubated in an avidin-biotin-horseradish peroxidase complex (Vector), washed in TRIS buffer and developed in 3,3&#x02032;-diaminobenzidine (0.5&#x02009;mg/ml; Sigma) with 0.005% H<sub>2</sub>O<sub>2</sub>. Sections were mounted onto slides and coverslipped, followed by visualization with an Olympus Vanox-T AH2 microscope and image capture using a Pixera Professional camera (VCS10132; Sherwood Dallas, Co., Dallas, TX, USA) that was connected to a personal computer. Images of the VTA ipsilateral and contralateral to the injection site were captured and each image was subsequently cropped to a fixed-size rectangle of 420&#x02009;&#x000D7;&#x02009;1238 pixels located within the parabrachial-paranigral subnuclei of the VTA (Phillipson, <xref ref-type="bibr" rid="B72">1979</xref>; Swanson, <xref ref-type="bibr" rid="B83">1982</xref>) for comparative analyses. In accordance with recent image guidelines (Couzin, <xref ref-type="bibr" rid="B23">2006</xref>), Adobe Photoshop (Adobe Systems, San Jose, CA, USA) was employed to mask dark shadows arising as injection artifacts on several sections.</p>
<p>The fixed-size images of the VTA were analyzed using a program written in Matlab (MathWorks, Inc., Natick, MA, USA) and the red channel of the image data was used for analysis (Hillman, <xref ref-type="bibr" rid="B42">1984</xref>; Pollandt et al., <xref ref-type="bibr" rid="B75">2005</xref>; Liu et al., <xref ref-type="bibr" rid="B54">2007</xref>). The intensity histogram was computed, producing a bell-shaped curve, skewed toward the dense side by the presence of darker (stained) pixels, which occupy a small fraction of the image area. The non-stained tissue density was modeled by fitting a normal curve to the upper portion of the histogram, using the Marquard non-linear least-squares method. The fitted curve was subtracted from the observed histogram on the dense side of the peak, providing an estimate of the intensity distribution of staining. A threshold was selected that was 2.6 standard deviations below the mean of the fitted background curve. Pixels darker than the threshold were considered to be stained and were displayed as a map for visual confirmation. The number of such pixels was counted to quantify immunolabeling (Hillman, <xref ref-type="bibr" rid="B42">1984</xref>; Pollandt et al., <xref ref-type="bibr" rid="B75">2005</xref>; Liu et al., <xref ref-type="bibr" rid="B54">2007</xref>). Total immunolabeling was determined as the sum of stained pixels weighted by their density below the staining threshold and was calculated from VTA images ipsilateral and contralateral to the infusion site. The difference in total immunolabeling from the ipsilateral minus contralateral VTA from each animal was compared between infusion groups with an unpaired Wilcoxon test.</p>
<p>To explore localization of 5-HT<sub>2A</sub>R within VTA cells and co-localization of 5-HT<sub>2A</sub>R in DA neurons, confocal microscopy (Bubar and Cunningham, <xref ref-type="bibr" rid="B12">2007</xref>; Bubar et al., <xref ref-type="bibr" rid="B16">2011</xref>; Anastasio et al., <xref ref-type="bibr" rid="B3">2013</xref>) was utilized to study double-label immunofluorescence with previously validated antibodies for the 5-HT<sub>2A</sub>R (Garlow et al., <xref ref-type="bibr" rid="B38">1993</xref>; Roth et al., <xref ref-type="bibr" rid="B77">1995</xref>; Cornea-Hebert et al., <xref ref-type="bibr" rid="B22">2002</xref>; Nocjar et al., <xref ref-type="bibr" rid="B66">2002</xref>; Bubar et al., <xref ref-type="bibr" rid="B15">2005</xref>) and tyrosine hydroxylase (TH; Browning et al., <xref ref-type="bibr" rid="B11">2005</xref>). Methods for immunofluorescence were similar to those described above with a few minor modifications. A separate cohort of rats (<italic>n</italic>&#x02009;&#x0003D;&#x02009;7) was unilaterally infused with lactated ringer&#x02019;s solution control or rAAV-5-HT<sub>2A</sub>R-Flag (as described above) and sacrificed 4&#x02009;weeks following infusion. Sections (25&#x02009;&#x003BC;m) were prepared using the Leica cryostat, followed by several washes and incubation in blocking serum (PBS-T plus 1.5% goat serum) as described above. Single sections were then incubated in PBS-T containing both the 5-HT<sub>2A</sub>R antibody (1:1000) and a monoclonal antibody for TH (1:2500; Immunostar). Sections were then washed in PBS and incubated in PBS-T containing secondary fluorescent goat-anti-rabbit (1:2000; Alexa fluor 555; Invitrogen, Carlsbad, CA, USA) and goat-anti-mouse (1:2000; Alexa fluor 488; Invitrogen) antibodies at room temperature. Last, sections were mounted as described above and labeling visualized at the UTMB Infectious Disease Optical Imaging Core using a Zeiss LSM 510 Meta confocal microscope and image capture with LSM 5 imaging software (Carl Zeiss Microimaging, Thornwood, NY, USA) that was connected to a personal computer.</p>
</sec>
</sec>
</sec>
<sec>
<title>Results</title>
<sec>
<title>Effects of 5-HT<sub>2A</sub>R overexpression on basal and cocaine-evoked activity</title>
<p>To test the hypothesis that overexpression of the 5-HT<sub>2A</sub>R in the VTA enhances basal or cocaine-evoked hyperactivity, male rats (<italic>n</italic>&#x02009;&#x0003D;&#x02009;10/group) were pretreated with intra-VTA infusion of either lactated Ringer&#x02019;s solution (control) or rAAV-5-HT<sub>2A</sub>R-Flag (virus). Of these, nine control rats exhibited needle placements positioned in the VTA (see below); one animal contained a needle placement outside of the VTA, and was thus excluded. Of virus-pretreated animals, five exhibited proper VTA placement as well as virally mediated overexpression of the 5-HT<sub>2A</sub>R (see below). One virus-pretreated animal exhibited overexpression in the hypothalamus as a result of incorrect placement, and four animals did not exhibit 5-HT<sub>2A</sub>R overexpression; these animals were excluded from analysis.</p>
<p>Basal locomotor activity measured on Days 7, 14, and 21 was analyzed for control animals with proper VTA placements and virus-pretreated animals with overexpression confined to the VTA (Figure <xref ref-type="fig" rid="F1">1</xref>). The levels of basal locomotor activity observed, regardless of pretreatment, were similar to levels of locomotor activity evoked upon saline injection in previous studies (McMahon and Cunningham, <xref ref-type="bibr" rid="B59">2001</xref>; McMahon et al., <xref ref-type="bibr" rid="B60">2001</xref>; Filip and Cunningham, <xref ref-type="bibr" rid="B35">2002</xref>; Bubar et al., <xref ref-type="bibr" rid="B14">2003</xref>). There was no main effect of pretreatment (<italic>F</italic><sub>1, 41</sub>&#x02009;&#x0003D;&#x02009;0.11, <italic>p</italic>&#x02009;&#x0003D;&#x02009;0.747), day (<italic>F</italic><sub>2, 41</sub>&#x02009;&#x0003D;&#x02009;3.17, <italic>p</italic>&#x02009;&#x0003D;&#x02009;0.06), or a pretreatment&#x02009;&#x000D7;&#x02009;day interaction (<italic>F</italic><sub>2, 41</sub>&#x02009;&#x0003D;&#x02009;3.18, <italic>p</italic>&#x02009;&#x0003D;&#x02009;0.06) observed for basal horizontal activity on Days 7, 14, and 21 after viral injections. <italic>A priori</italic> comparisons indicated that the basal horizontal activity did not differ between pretreatment groups on any test day (Figure <xref ref-type="fig" rid="F1">1</xref>A). For basal rearing activity, a main effect of day (<italic>F</italic><sub>2, 41</sub>&#x02009;&#x0003D;&#x02009;10.97, <italic>p</italic>&#x02009;&#x0003D;&#x02009;0.0004) in the absence of a main effect of pretreatment (<italic>F</italic><sub>1, 41</sub>&#x02009;&#x0003D;&#x02009;0.65, <italic>p</italic>&#x02009;&#x0003D;&#x02009;0.435) or a pretreatment&#x02009;&#x000D7;&#x02009;day interaction (<italic>F</italic><sub>2, 41</sub>&#x02009;&#x0003D;&#x02009;0.46, <italic>p</italic>&#x02009;&#x0003D;&#x02009;0.638) was observed (Figure <xref ref-type="fig" rid="F1">1</xref>B); <italic>a priori</italic> comparisons between treatment groups failed to indicate significant differences in basal rearing activity between control and virus treatment groups on any given test day. Levels of basal activity in animals with misplaced rAAV-5-HT<sub>2A</sub>R-Flag infusions outside of the VTA did not differ from control animals on days 7, 14, or 21 (data not shown; <italic>p</italic>&#x02009;&#x0003E;&#x02009;0.05).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption><p><bold>Basal levels of motility are unchanged following intra-VTA infusion of rAAV-5-HT<sub>2A</sub>R-Flag</bold>. Mean total horizontal <bold>(A)</bold> or rearing activity <bold>(B)</bold> [counts/60&#x02009;min (&#x000B1;SEM)] were recorded 7, 14, and 21 days following intracerebral pretreatment with 2&#x02009;&#x003BC;l of vehicle (Control; open bar; <italic>n</italic>&#x02009;&#x0003D;&#x02009;9) or rAAV-5-HT<sub>2A</sub>R-Flag (Virus, filled bar; <italic>n</italic>&#x02009;&#x0003D;&#x02009;5). Both pretreatment groups exhibited similar levels of horizontal and rearing activity on each day analyzed.</p></caption>
<graphic xlink:href="fpsyt-04-00002-g001.tif"/>
</fig>
<p>On Day 21 following the measurement of basal locomotor activity, all animals were challenged with 15&#x02009;mg/kg of cocaine and activity was recorded for 60&#x02009;min (Figure <xref ref-type="fig" rid="F2">2</xref>). A main effect of pretreatment (<italic>F</italic><sub>1, 83</sub>&#x02009;&#x0003D;&#x02009;7.84, <italic>p</italic>&#x02009;&#x0003D;&#x02009;0.016), time (<italic>F</italic><sub>5, 83</sub>&#x02009;&#x0003D;&#x02009;28.37, <italic>p</italic>&#x02009;&#x0003C;&#x02009;0.0001), and a pretreatment&#x02009;&#x000D7;&#x02009;time interaction (<italic>F</italic><sub>5, 83</sub>&#x02009;&#x0003D;&#x02009;28.37, <italic>p</italic>&#x02009;&#x0003C;&#x02009;0.0001) were observed for cocaine-evoked horizontal activity measured in 10-min time bins during the 60-min test (Figure <xref ref-type="fig" rid="F2">2</xref>A, left panel). <italic>A priori</italic> comparisons indicated that viral pretreatment was associated with significantly greater cocaine-evoked horizontal activity during each of the first two time bins (10 and 20&#x02009;min) of the test period as compared to control animals (<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.008/comparison). A trend for increased cocaine-evoked horizontal activity was observed but not statistically significant at the 30&#x02009;min (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.04) and 40&#x02009;min time bins (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.04). The <italic>a priori</italic> analysis indicated that virus pretreatment was associated with significantly greater levels of cocaine-evoked horizontal activity totaled for the entire 60-min test session (Figure <xref ref-type="fig" rid="F2">2</xref>A, right panel; <italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05). Levels of cocaine-evoked horizontal activity in animals with misplaced rAAV-5-HT<sub>2A</sub>R-Flag infusions outside of the VTA did not differ from control animals (data not shown; <italic>p</italic>&#x02009;&#x0003E;&#x02009;0.05).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption><p><bold>Intra-VTA infusion of rAAV-5-HT<sub>2A</sub>R-Flag is associated with elevated cocaine-induced motility</bold>. Data represent the mean total horizontal <bold>(A)</bold> or rearing activity <bold>(B)</bold> in rats induced upon injection with cocaine (15&#x02009;mg/kg, ip) 21&#x02009;days after a 2&#x02009;&#x003BC;l infusion of vehicle (Control; open symbols; <italic>n</italic>&#x02009;&#x0003D;&#x02009;9) or rAAV-5-HT<sub>2A</sub>R-Flag (Virus; filled symbols; <italic>n</italic>&#x02009;&#x0003D;&#x02009;5). Left panels represent the <italic>timecourse</italic> across the 60&#x02009;min session divided into 10&#x02009;min bins [mean activity counts/10&#x02009;min (&#x000B1;SEM)]; &#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.008 vs. control at same time point. Right panels illustrate mean total horizontal <bold>(A)</bold> or rearing activity <bold>(B)</bold> for the entire 60&#x02009;min session [counts/60&#x02009;min (&#x000B1;SEM); &#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05 vs. control. Dashed line represents average level of basal horizontal or rearing activity determined in the 60&#x02009;min period prior to cocaine injection (see Figure <xref ref-type="fig" rid="F1">1</xref>).</p></caption>
<graphic xlink:href="fpsyt-04-00002-g002.tif"/>
</fig>
<p>Rearing activity was also measured following cocaine injection on Day 21. A main effect of pretreatment (<italic>F</italic><sub>1, 83</sub>&#x02009;&#x0003D;&#x02009;6.61, <italic>p</italic>&#x02009;&#x0003D;&#x02009;0.025) and a pretreatment&#x02009;&#x000D7;&#x02009;time interaction (<italic>F</italic><sub>5, 83</sub>&#x02009;&#x0003D;&#x02009;3.13, <italic>p</italic>&#x02009;&#x0003D;&#x02009;0.014), but not a main effect of time (<italic>F</italic><sub>5, 83</sub>&#x02009;&#x0003D;&#x02009;0.82, <italic>p</italic>&#x02009;&#x0003D;&#x02009;0.538), were observed for cocaine-evoked rearing activity measured in 10-min time bins during the 60-min test (Figure <xref ref-type="fig" rid="F2">2</xref>B). <italic>A priori</italic> planned comparisons indicated that the viral pretreatment was associated with greater cocaine-evoked rearing activity at the 50&#x02009;min time bin (<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.008/comparison), with the comparisons made at the 30&#x02009;min (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.047), 40&#x02009;min (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.01), and 60&#x02009;min time bins (<italic>p</italic>&#x02009;&#x0003D;&#x02009;0.023) of the test period approaching statistical significance (Figure <xref ref-type="fig" rid="F2">2</xref>B, left panel). The <italic>a priori</italic> analysis indicated that virus pretreatment was associated with significantly greater levels of cocaine-evoked rearing activity totaled across the entire 60-min test session compared to control animals (Figure <xref ref-type="fig" rid="F2">2</xref>B, left panel; <italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05). Levels of cocaine-evoked rearing activity in animals with misplaced rAAV-5-HT<sub>2A</sub>R-Flag infusions outside of the VTA did not differ from control animals (data not shown; <italic>p</italic>&#x02009;&#x0003E;&#x02009;0.05).</p>
</sec>
<sec>
<title>5-HT<sub>2A</sub>R and Flag immunohistochemistry</title>
<p>Following the completion of behavioral testing on Day 21, animals were sacrificed and immunohistochemistry performed to confirm overexpression of 5-HT<sub>2A</sub>R and expression of Flag in the VTA (Figure <xref ref-type="fig" rid="F3">3</xref>). A representative photomicrograph depicting 5-HT<sub>2A</sub>R immunolabeling in the VTA ipsilateral to the infusion site from a control animal illustrates that the majority of the 5-HT<sub>2A</sub>R immunoreactivity seems to be confined to cell bodies, with little fiber labeling (Figure <xref ref-type="fig" rid="F3">3</xref>A). Control animals exhibited little Flag background labeling (Figure <xref ref-type="fig" rid="F3">3</xref>B). In contrast, 5-HT<sub>2A</sub>R immunolabeling in the ipsilateral VTA from a virus animal infused with rAAV-5-HT<sub>2A</sub>R-Flag (Figure <xref ref-type="fig" rid="F3">3</xref>C) illustrates a distinct pattern of 5-HT<sub>2A</sub>R immunolabeling characterized by robust 5-HT<sub>2A</sub>R immunoreactivity in both cell bodies and fibers. A brain section labeled with the anti-Flag antibody and adjacent to that shown in Figure <xref ref-type="fig" rid="F3">3</xref>C shows a similar expression of immunoreactivity, with labeled cell bodies as well as fibers (Figure <xref ref-type="fig" rid="F3">3</xref>D). Additionally, the arrows indicate labeled cells in Figures <xref ref-type="fig" rid="F3">3</xref>C,D seem to be identical, providing further evidence of successful overexpression.</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption><p><bold>Intra-VTA infusion of rAAV-5-HT<sub>2A</sub>R-Flag is associated with overexpression of 5-HT<sub>2A</sub>R and Flag peptide immunolabeling</bold>. Shown are representative photomicrographs of <bold>(A)</bold> anti-5-HT<sub>2A</sub>R antibody labeling of VTA neurons in control animals; <bold>(B)</bold> anti-Flag antibody labeling of VTA neurons in control animals; <bold>(C)</bold> anti-5-HT<sub>2A</sub>R antibody labeling of VTA neurons in virus animals infused with rAAV-5-HT<sub>2A</sub>R-Flag; <bold>(D)</bold> labeling with anti-Flag antibody in an immediately adjacent tissue section of virus-pretreated animal indicates co-localization of 5-HT<sub>2A</sub>R and Flag. <bold>(E)</bold> Quantification of net 5-HT<sub>2A</sub>R immunoreactivity (&#x000B1;SEM) in VTA of control animals (open bar; <italic>n</italic>&#x02009;&#x0003D;&#x02009;9) vs. virus animals infused with rAAV-5-HT<sub>2A</sub>R-Flag-(filled bar; <italic>n</italic>&#x02009;&#x0003D;&#x02009;5). Animals that previously received intra-VTA viral infusion exhibited greater 5-HT<sub>2A</sub>R immunoreactivity than control animals, confirming viral overexpression of 5-HT<sub>2A</sub>R. <bold>(F)</bold> Quantification of net Flag immunoreactivity (&#x000B1;SEM) in VTA of control animals (open bar; <italic>n</italic>&#x02009;&#x0003D;&#x02009;9) vs. virus animals infused with rAAV-5-HT<sub>2A</sub>R-Flag (filled bar; <italic>n</italic>&#x02009;&#x0003D;&#x02009;5). Animals that previously received intra-VTA viral infusion exhibited greater Flag immunoreactivity than those control animals, further confirming viral overexpression of 5-HT<sub>2A</sub>R. Scale bar&#x02009;&#x0003D;&#x02009;20&#x02009;&#x003BC;m. &#x0002A;<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05 vs. control.</p></caption>
<graphic xlink:href="fpsyt-04-00002-g003.tif"/>
</fig>
<p>A comparison of the 5-HT<sub>2A</sub>R immunoreactivity quantified in the VTA (Figure <xref ref-type="fig" rid="F3">3</xref>E) was made using an unpaired Wilcoxon test. Control animals exhibited similar, moderate levels of 5-HT<sub>2A</sub>R immunoreactivity in the VTA ipsilateral (Figure <xref ref-type="fig" rid="F3">3</xref>A) and contralateral (data not shown) to the infusion site. Infusion of rAAV-5-HT<sub>2A</sub>R-Flag resulted in overexpression of 5-HT<sub>2A</sub>R in the ipsilateral (Figure <xref ref-type="fig" rid="F3">3</xref>C), but not contralateral, VTA (data not shown). The total net immunolabeling (ipsilateral immunolabeling &#x02013; contralateral immunolabeling) was then calculated in individual animals in order to normalize 5-HT<sub>2A</sub>R overexpression to basal 5-HT<sub>2A</sub>R levels in the brain hemisphere contralateral to viral infusion. This total net immunolabeling was then compared between pretreatment groups and the results indicate that greater levels of 5-HT<sub>2A</sub>R expression were exhibited in virus-pretreated animals (<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05; Figure <xref ref-type="fig" rid="F3">3</xref>E). Quantification of Flag immunoreactivity with this same procedure also revealed robust levels of Flag labeling in virus-pretreated animals, as compared to control animals (<italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05; Figure <xref ref-type="fig" rid="F3">3</xref>F), further confirming successful expression of the transgene. Levels of 5-HT<sub>2A</sub>R and Flag immunoreactivity in animals with misplaced rAAV-5-HT<sub>2A</sub>R-Flag infusions outside of the VTA did not differ from control animals (data not shown; <italic>p</italic>&#x02009;&#x0003E;&#x02009;0.05).</p>
<p>Confocal microscopy was utilized to analyze tissue sections processed for double-labeled 5-HT<sub>2A</sub>R and TH immunofluorescence in the VTA in order to assess localization of 5-HT<sub>2A</sub>R to DA neurons (Figure <xref ref-type="fig" rid="F4">4</xref>) from animals pretreated with vehicle (Figure <xref ref-type="fig" rid="F4">4</xref>A) or AAV-5-HT<sub>2A</sub>R-Flag (Figures <xref ref-type="fig" rid="F4">4</xref>B&#x02013;F). Figure <xref ref-type="fig" rid="F4">4</xref>A demonstrates a composite confocal image (24 sections, 0.68&#x02009;&#x003BC;m/slice) of 5-HT<sub>2A</sub>R immunoreactivity from the VTA of a control animal. Immunolabeling is predominantly confined to cell body regions (Figure <xref ref-type="fig" rid="F4">4</xref>A) in keeping with our observation of 5-HT<sub>2A</sub>R staining using DAB (above; Figure <xref ref-type="fig" rid="F3">3</xref>) and previous studies using the same anti-5-HT<sub>2A</sub>R antibody (Nocjar et al., <xref ref-type="bibr" rid="B66">2002</xref>; Bubar et al., <xref ref-type="bibr" rid="B15">2005</xref>). Figure <xref ref-type="fig" rid="F4">4</xref>B demonstrates a composite confocal image (24 sections, 0.70&#x02009;&#x003BC;m/slice) of 5-HT<sub>2A</sub>R immunoreactivity in the VTA of an animal infused with rAAV-5-HT<sub>2A</sub>R-Flag. Overexpression is indicated by the robust immunoreactivity in both cell bodies and fibers (Figure <xref ref-type="fig" rid="F4">4</xref>B). Figures <xref ref-type="fig" rid="F4">4</xref>C&#x02013;F represents composite confocal images of double-label immunofluorescence from an animal infused with rAAV-5-HT<sub>2A</sub>R-Flag. Figure <xref ref-type="fig" rid="F4">4</xref>C demonstrates a composite confocal image (24 sections, 0.71&#x02009;&#x003BC;m/slice) of 5-HT<sub>2A</sub>R immunoreactivity in the VTA of an animal infused with AAV-5-HT<sub>2A</sub>R-Flag, and Figure <xref ref-type="fig" rid="F4">4</xref>D demonstrates immunoreactivity for TH in the same tissue section as that shown in Figure <xref ref-type="fig" rid="F4">4</xref>C. The composite image represents localization of 5-HT<sub>2A</sub>R immunoreactivity in a TH-positive cell (Figure <xref ref-type="fig" rid="F4">4</xref>E). Additionally, 20 of the serial <italic>Z</italic>-sections that comprise the composite image in Figure <xref ref-type="fig" rid="F4">4</xref>E are shown in Figure <xref ref-type="fig" rid="F4">4</xref>F (Bubar and Cunningham, <xref ref-type="bibr" rid="B12">2007</xref>; Bubar et al., <xref ref-type="bibr" rid="B16">2011</xref>; Anastasio et al., <xref ref-type="bibr" rid="B3">2013</xref>).</p>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption><p><bold>Confocal microscopy demonstrates robust 5-HT<sub>2A</sub>R labeling in the VTA and co-localization in cells immunopositive for tyrosine hydroxylase (TH)</bold>. <bold>(A)</bold> Representative composite confocal image (24 slices, 0.68&#x02009;&#x003BC;m/slice) demonstrates 5-HT<sub>2A</sub>R immunoreactivity (red) in VTA neurons from control animals. <bold>(B)</bold> Representative composite confocal image (24 slices, 0.7&#x02009;&#x003BC;m/slice) demonstrates 5-HT<sub>2A</sub>R immunoreactivity (red) in VTA neurons from virus animals pretreated with rAAV-5-HT<sub>2A</sub>R-Flag. <bold>(C&#x02013;F)</bold> Representative composite confocal image (24 slices, 0.71&#x02009;&#x003BC;m/slice) demonstrating co-localization of 5-HT<sub>2A</sub>R and TH in VTA neurons from virus animals pretreated with rAAV-5-HT<sub>2A</sub>R-Flag. In the same tissue section, there is robust 5-HT<sub>2A</sub>R immunoreactivity <bold>(C)</bold> and TH immunoreactivity <bold>(D)</bold> that is colocalized to the same cells <bold>(E)</bold>. <bold>(F)</bold> Contains 20 of the <italic>Z</italic>-sections that make up the composite image. Scale bar&#x02009;&#x0003D;&#x02009;5&#x02009;&#x003BC;m.</p></caption>
<graphic xlink:href="fpsyt-04-00002-g004.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>The present study is the first to demonstrate that overexpression of 5-HT<sub>2A</sub>R protein in the VTA enhances the behavioral effects of cocaine following successful virally mediated overexpression of the 5-HT<sub>2A</sub>R in the adult rat. Intra-VTA transduction with the rAAV-5-HT<sub>2A</sub>R-Flag vector, which produced quantifiable overexpression of 5-HT<sub>2A</sub>R and appearance of the Flag protein in VTA neurons, had little effect on basal levels of motor activity, but significantly enhanced cocaine-evoked motility relative to controls. These results are in line with an overall facilitatory role for the 5-HT<sub>2A</sub>R in mediating cocaine-evoked behaviors (see, Bubar and Cunningham, <xref ref-type="bibr" rid="B13">2008</xref>; Nic Dhonnchadha and Cunningham, <xref ref-type="bibr" rid="B64">2008</xref>) and support the hypothesis that the VTA is a key site of action for the 5-HT<sub>2A</sub>R to control the behavioral effects of cocaine.</p>
<p>The current results revealing that overexpression of 5-HT<sub>2A</sub>R in the VTA enhances cocaine-evoked hyperactivity are in accordance with a previous study from our laboratory demonstrating that intra-VTA microinjection of the selective 5-HT<sub>2A</sub>R antagonist M100907 blocked cocaine-evoked hyperactivity (McMahon et al., <xref ref-type="bibr" rid="B60">2001</xref>). These effects parallel those of systemic injection of 5-HT<sub>2A</sub>R ligands, as 5-HT<sub>2A</sub>R <italic>antagonists</italic> block and 5-HT<sub>2A</sub>R <italic>agonists</italic> enhance the hypermotive effects of cocaine (McMahon and Cunningham, <xref ref-type="bibr" rid="B59">2001</xref>; Fletcher et al., <xref ref-type="bibr" rid="B36">2002</xref>; Filip et al., <xref ref-type="bibr" rid="B33">2004</xref>) and other stimulants (Auclair et al., <xref ref-type="bibr" rid="B5">2004</xref>; Herin et al., <xref ref-type="bibr" rid="B41">2005</xref>). These data implicate the VTA as a critical site of action for the positive modulatory control of 5-HT<sub>2A</sub>R over psychostimulant-evoked motor activity. This stimulatory role for VTA 5-HT<sub>2A</sub>R upon cocaine-evoked hypermotility appears to occur in the absence of an apparent tonic regulatory influence of this receptor on motor activity. Overexpression of the 5-HT<sub>2A</sub>R in the VTA has no effect upon basal levels of motility evoked upon exposure to the activity monitors. These data are consistent with studies in the literature demonstrating that selective blockade of 5-HT<sub>2A</sub>R in the VTA does not alter spontaneous locomotor behavior (McMahon et al., <xref ref-type="bibr" rid="B60">2001</xref>; Auclair et al., <xref ref-type="bibr" rid="B5">2004</xref>). However, we have observed the enhancement of motor activity upon intra-VTA infusion of the non-selective 5-HT<sub>2A</sub>R agonist DOI (Herin et al., unpublished observations). Together, these data indicate that, despite robust enhancement of 5-HT<sub>2A</sub>R immunoreactivity in both cell bodies and fibers relative to controls, elevated expression of the 5-HT<sub>2A</sub>R in the VTA alone is not sufficient to induce overt alterations in basal motor activation. However, the elevated VTA 5-HT<sub>2A</sub>R expression generates an augmented and positive modulatory effect over cocaine-evoked hyperactivity.</p>
<p>Several characteristics of the 5-HT<sub>2A</sub>R may account for the low levels of basal 5-HT<sub>2A</sub>R function. For example, the 5-HT<sub>2A</sub>R exhibits moderate affinity for 5-HT (Peroutka, <xref ref-type="bibr" rid="B70">1986</xref>; Rothman et al., <xref ref-type="bibr" rid="B78">2000</xref>; Leysen, <xref ref-type="bibr" rid="B53">2004</xref>) and possesses modest constitutive activity in the absence of ligand binding (Berg et al., <xref ref-type="bibr" rid="B7">2005</xref>). In addition, although the 5-HT<sub>2A</sub>R is thought to primarily localize to somata or dendrites postsynaptic to 5-HT terminals, ultrastructural localization studies indicate that the receptor prominently localizes to the cytoplasm, rather than the plasma membrane, and is primarily found in extrasynaptic regions (Cornea-Hebert et al., <xref ref-type="bibr" rid="B21">1999</xref>; Doherty and Pickel, <xref ref-type="bibr" rid="B29">2000</xref>). Such localization patterns suggest that a component of 5-HT actions at the 5-HT<sub>2A</sub>R may occur via paracrine or volume transmission which may be minimal at baseline (Miner et al., <xref ref-type="bibr" rid="B62">2000</xref>; Jansson et al., <xref ref-type="bibr" rid="B46">2001</xref>). Thus, activation of the 5-HT<sub>2A</sub>R receptors in VTA may only occur during periods of stimulated 5-HT release like that evoked following systemic cocaine administration (Chen and Reith, <xref ref-type="bibr" rid="B20">1994</xref>).</p>
<p>The differential effects of 5-HT<sub>2A</sub>R antagonists delivered into the VTA upon basal vs. cocaine-stimulated motor activity have been attributed to their efficacy to alter the activation status of the DA mesoaccumbens pathway to control locomotor activity (Kelly and Iversen, <xref ref-type="bibr" rid="B49">1976</xref>; Broderick et al., <xref ref-type="bibr" rid="B10">2004</xref>), and are in accordance with a prevailing hypothesis that the 5-HT<sub>2A</sub>R modulates DA mesocorticoaccumbens neurotransmission only under &#x0201C;stimulated&#x0201D; conditions (Schmidt et al., <xref ref-type="bibr" rid="B79">1992</xref>; De Deurwaerdere and Spampinato, <xref ref-type="bibr" rid="B25">1999</xref>; Di Giovanni et al., <xref ref-type="bibr" rid="B28">1999</xref>; Bonaccorso et al., <xref ref-type="bibr" rid="B9">2002</xref>; Kuroki et al., <xref ref-type="bibr" rid="B51">2003</xref>; Auclair et al., <xref ref-type="bibr" rid="B5">2004</xref>). In accordance with the lack of effects of intra-VTA administration of 5-HT<sub>2A</sub>R antagonists on basal levels of motor activation (McMahon et al., <xref ref-type="bibr" rid="B60">2001</xref>; Auclair et al., <xref ref-type="bibr" rid="B5">2004</xref>), local infusion of 5-HT<sub>2A</sub>R antagonists into the VTA failed to alter basal DA release in the NAc (Auclair et al., <xref ref-type="bibr" rid="B5">2004</xref>), nor did perfusion of 5-HT<sub>2A</sub>R antagonists alter firing rates of VTA DA neurons in a midbrain slice preparation (Olijslagers et al., <xref ref-type="bibr" rid="B67">2004</xref>). Conversely, intra-VTA 5-HT<sub>2A</sub>R antagonist administration significantly blocked systemic cocaine- (McMahon et al., <xref ref-type="bibr" rid="B60">2001</xref>) and amphetamine-evoked hypermotility (Auclair et al., <xref ref-type="bibr" rid="B5">2004</xref>) and associated amphetamine-evoked NAc DA release (Auclair et al., <xref ref-type="bibr" rid="B5">2004</xref>). Thus the selective effects of VTA 5-HT<sub>2A</sub>R overexpression upon cocaine-evoked as opposed to basal motor activity are likely due to 5-HT<sub>2A</sub>R-mediated facilitation of DA mesoaccumbens neurotransmission under stimulated vs. tonic conditions, respectively.</p>
<p>The 5-HT<sub>2A</sub>R is natively resident within DA and non-DAergic (GABA- or possibly glutamate-containing) neurons in the VTA (Doherty and Pickel, <xref ref-type="bibr" rid="B29">2000</xref>; Ikemoto et al., <xref ref-type="bibr" rid="B44">2000</xref>; Nocjar et al., <xref ref-type="bibr" rid="B66">2002</xref>; Yamaguchi et al., <xref ref-type="bibr" rid="B90">2007</xref>) although DA neurons comprise the majority of VTA neuronal cells (Swanson, <xref ref-type="bibr" rid="B83">1982</xref>; Johnson and North, <xref ref-type="bibr" rid="B47">1992</xref>; Ikemoto, <xref ref-type="bibr" rid="B45">2007</xref>). Indeed, our confocal immunofluorescence studies (see Figure <xref ref-type="fig" rid="F4">4</xref>) provide evidence of 5-HT<sub>2A</sub>R overexpression in VTA DA neurons. Activation of elevated levels of 5-HT<sub>2A</sub>R resident in DA neurons consequent to cocaine-evoked elevations in 5-HT efflux (Chen and Reith, <xref ref-type="bibr" rid="B20">1994</xref>) would be expected to increase activity of DA neurons (Pessia et al., <xref ref-type="bibr" rid="B71">1994</xref>) and release of DA in terminal regions (De Deurwaerdere and Spampinato, <xref ref-type="bibr" rid="B25">1999</xref>). As noted above, enhanced DA release in the NAc correlates positively with generation of hypermotility (Kelly and Iversen, <xref ref-type="bibr" rid="B49">1976</xref>). Thus, overexpression of 5-HT<sub>2A</sub>R within DA neurons that project to the NAc would serve to enhance cocaine-evoked hyperactivity, as was observed in the present study. Although the overexpression of 5-HT<sub>2A</sub>R in the DA neurons aligns with the observed behavioral profile, 5-HT<sub>2A</sub>R overexpression also likely occurred in non-DAergic VTA neurons, presumably GABA interneurons and/or projection neurons, or possibly glutamate neurons (Yamaguchi et al., <xref ref-type="bibr" rid="B90">2007</xref>; see Figure <xref ref-type="fig" rid="F4">4</xref>), since the constitutively active promoter utilized evokes gene expression in all neuronal cell types (Kaplitt et al., <xref ref-type="bibr" rid="B48">2007</xref>; St Martin et al., <xref ref-type="bibr" rid="B81">2007</xref>). Future studies employing a promotor that would direct viral expression to either DA, GABA, or glutamate neurons would help to discern the contribution of 5-HT<sub>2A</sub>R overexpression within the particular neuronal cell type to basal vs. cocaine-evoked locomotor activity.</p>
<p>The behavioral phenotype observed following rAAV-5-HT<sub>2A</sub>R-Flag infusion is most likely mediated by neurons intrinsic to the VTA. Measurable 5-HT<sub>2A</sub>R overexpression was confined to the site of infusion, and adjacent brain regions (especially, substantia nigra; data not shown) did not demonstrate patterns of 5-HT<sub>2A</sub>R overexpression. Second, in keeping with this observation, cells projecting to the VTA were not likely to be transduced, as the virus utilized in these studies (AAV-2) is not readily transported retrogradely following infusion into the brain (Chamberlin et al., <xref ref-type="bibr" rid="B19">1998</xref>). Third, the cells transduced in the VTA fit the morphological profile suggestive of neurons, consistent with previous observations that AAV-2 does not readily transduce glial cells (Chamberlin et al., <xref ref-type="bibr" rid="B19">1998</xref>). Fourth, while theoretically possible that viral vector transduction <italic>per se</italic> could evoke behaviorally relevant cellular changes, this possibility is highly unlikely. Previous studies have shown that transduction of neural tissue with AAV vectors does not alter the electrophysiological properties of neurons (Ehrengruber et al., <xref ref-type="bibr" rid="B31">2001</xref>) or result in neurotoxicity (Lo et al., <xref ref-type="bibr" rid="B56">1999</xref>), while animals infused intracranially with either vehicle or control viral vectors (Carlezon Jr. et al., <xref ref-type="bibr" rid="B18">1997</xref>; Pliakas et al., <xref ref-type="bibr" rid="B73">2001</xref>), including AAV (Landgraf et al., <xref ref-type="bibr" rid="B52">2003</xref>), exhibit equally normal patterns of behavior. Basal locomotor activity did not differ between the animals infused with control vs. AAV in the present study, and the levels of activity observed were similar to that reported in previous studies following saline injection studies (McMahon and Cunningham, <xref ref-type="bibr" rid="B59">2001</xref>; McMahon et al., <xref ref-type="bibr" rid="B60">2001</xref>; Filip and Cunningham, <xref ref-type="bibr" rid="B35">2002</xref>; Bubar et al., <xref ref-type="bibr" rid="B14">2003</xref>). Finally, animals with rAAV-5-HT<sub>2A</sub>R-Flag infusions located outside the VTA exhibited levels of cocaine-evoked hyperactivity similar to that of control animals. Altogether, these data point to the overexpression of 5-HT<sub>2A</sub>R in the VTA as the most likely contributor to the observed enhancement of cocaine-evoked hyperactivity following rAAV-5-HT<sub>2A</sub>R-Flag infusion.</p>
<p>The results of present study suggest that expression levels of the 5-HT<sub>2A</sub>R in the VTA regulate vulnerability to the hypermotive effects of cocaine and support a possible role for VTA 5-HT<sub>2A</sub>R in modulating other behavioral effects of cocaine mediated by DA mesocorticoaccumbens circuitry. In addition to altering cocaine-evoked hyperactivity, systemic administration of 5-HT<sub>2A</sub>R antagonists has been shown to reduce the discriminative stimulus effects of cocaine (McMahon and Cunningham, <xref ref-type="bibr" rid="B59">2001</xref>; Filip et al., <xref ref-type="bibr" rid="B34">2006</xref>) and cocaine-evoked behavioral disinhibition (i.e., impulsivity; Anastasio et al., <xref ref-type="bibr" rid="B4">2011</xref>; Fletcher et al., <xref ref-type="bibr" rid="B37">2011</xref>), as well as to block expression of cocaine sensitization (Filip et al., <xref ref-type="bibr" rid="B33">2004</xref>; Zayara et al., <xref ref-type="bibr" rid="B91">2011</xref>). Furthermore, although the 5-HT<sub>2A</sub>R does not appear to modulate cocaine intake in the self-administration assay (Fletcher et al., <xref ref-type="bibr" rid="B36">2002</xref>; Nic Dhonnchadha et al., <xref ref-type="bibr" rid="B65">2009</xref>), 5-HT<sub>2A</sub>R antagonists have been shown to attenuate both cocaine- and cue-evoked reinstatement of cocaine-seeking (Fletcher et al., <xref ref-type="bibr" rid="B36">2002</xref>; Nic Dhonnchadha et al., <xref ref-type="bibr" rid="B65">2009</xref>). However, no studies have evaluated specifically the role of VTA 5-HT<sub>2A</sub>R receptors in cocaine-evoked behaviors other than locomotor hyperactivity (McMahon et al., <xref ref-type="bibr" rid="B60">2001</xref>), though 5-HT<sub>2A</sub>R in the NAc (Zayara et al., <xref ref-type="bibr" rid="B91">2011</xref>) and PFC (Pockros et al., <xref ref-type="bibr" rid="B74">2011</xref>) have been implicated in sensitization and cue-evoked reinstatement of cocaine-seeking, respectively. Here we employed a single, low dose of cocaine (15&#x02009;mg/kg) that consistently induces hypermotility in the absence of overt stereotypic behaviors (Herges and Taylor, <xref ref-type="bibr" rid="B40">1998</xref>) to further establish a critical role for VTA 5-HT<sub>2A</sub>R in the hypermotive effects of cocaine. Even with the small sample size employed in the current study, the behavioral response to the single dose of cocaine produced a robust behavioral response with little variability. Our results combined with the knowledge regarding 5-HT<sub>2A</sub>R regulation of DA mesocorticoaccumbens activation provide the impetus to conduct more thorough investigations into the role of 5-HT<sub>2A</sub>R regulation in the VTA not only in the hypermotive effects of cocaine, but also more complex cocaine-associated behaviors. Furthermore, the methods established here utilizing rAAV-5-HT<sub>2A</sub>R-Flag to overexpress the 5-HT<sub>2A</sub>R can be employed to evaluate the role of elevated 5-HT<sub>2A</sub>R expression throughout the brain.</p>
</sec>
<sec>
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<p>This research was supported by National Institute on Drug Abuse grants DA 000260, DA 006511, DA 015272, DA 020087, DA 024157. The 5-HT<sub>2A</sub>R cDNA and RN46A cells were kindly provided by Dr. J. Liu (University of Cincinnati) and Dr. Scott Whittemore (University of Miami), respectively. The authors would also like to thank Dr. D. J. Poulsen (University of Montana) for a gift of the pCW plasmid, Dr. Bryan Roth (University of North Carolina) for the polyclonal 5-HT<sub>2A</sub>R antibody as well as the National Institute on Drug Abuse for providing (-)-cocaine. Assistance with confocal microscopy was kindly provided by the Dr. Thomas Albrecht and Eugene Knutson at the UTMB Infectious Disease Optical Imaging Core Facility. We also thank Dr. William Carlezon (Harvard University) for his assistance with the establishment of these techniques. This manuscript was presented by David V. Herin in partial fulfillment of the requirements for the Ph.D. degree for the Graduate School of Biomedical Sciences at the University of Texas Medical Branch.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alex</surname> <given-names>K. D.</given-names></name> <name><surname>Pehek</surname> <given-names>E. A.</given-names></name></person-group> (<year>2007</year>). <article-title>Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission</article-title>. <source>Pharmacol. Ther.</source> <volume>113</volume>, <fpage>296</fpage>&#x02013;<lpage>320</lpage>.<pub-id pub-id-type="doi">10.1016/j.pharmthera.2006.08.004</pub-id><pub-id pub-id-type="pmid">17049611</pub-id></citation></ref>
<ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname> <given-names>A. R.</given-names></name> <name><surname>MacPhail</surname> <given-names>R. C.</given-names></name></person-group> (<year>1991</year>). <article-title>Effects of triadimefon on a multiple schedule of fixed-interval performance: comparison with methylphenidate, d-amphetamine and chlorpromazine</article-title>. <source>Pharmacol. Biochem. Behav.</source> <volume>40</volume>, <fpage>775</fpage>&#x02013;<lpage>780</lpage>.<pub-id pub-id-type="doi">10.1016/0091-3057(91)90085-G</pub-id><pub-id pub-id-type="pmid">1816565</pub-id></citation></ref>
<ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anastasio</surname> <given-names>N. C.</given-names></name> <name><surname>Gilbertson</surname> <given-names>S. R.</given-names></name> <name><surname>Bubar</surname> <given-names>M. J.</given-names></name> <name><surname>Agarkov</surname> <given-names>A.</given-names></name> <name><surname>Stutz</surname> <given-names>S. J.</given-names></name> <name><surname>Jeng</surname> <given-names>Y. J.</given-names></name> <etal/></person-group> (<year>2013</year>). <article-title>Peptide inhibitors disrupt the serotonin 5-HT2C receptor interaction with phosphatase and tensin homologue (PTEN) to allosterically modulate cellular signaling and behavior</article-title>. <source>J. Neurosci.</source> <volume>33</volume>, <fpage>1615</fpage>&#x02013;<lpage>1630</lpage>.<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2656-12.2013</pub-id><pub-id pub-id-type="pmid">23345234</pub-id></citation></ref>
<ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anastasio</surname> <given-names>N. C.</given-names></name> <name><surname>Stoffel</surname> <given-names>E. C.</given-names></name> <name><surname>Fox</surname> <given-names>R. G.</given-names></name> <name><surname>Bubar</surname> <given-names>M. J.</given-names></name> <name><surname>Rice</surname> <given-names>K. C.</given-names></name> <name><surname>Moeller</surname> <given-names>F. G.</given-names></name> <etal/></person-group> (<year>2011</year>). <article-title>Serotonin (5-hydroxytryptamine) 5-HT2A receptor: Association with inherent and cocaine-evoked behavioral disinhibition in rats</article-title>. <source>Behav. Pharmacol.</source> <volume>22</volume>, <fpage>248</fpage>&#x02013;<lpage>261</lpage>.<pub-id pub-id-type="doi">10.1097/FBP.0b013e328345f90d</pub-id><pub-id pub-id-type="pmid">21499079</pub-id></citation></ref>
<ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Auclair</surname> <given-names>A.</given-names></name> <name><surname>Blanc</surname> <given-names>G.</given-names></name> <name><surname>Glowinski</surname> <given-names>J.</given-names></name> <name><surname>Tassin</surname> <given-names>J. P.</given-names></name></person-group> (<year>2004</year>). <article-title>Role of serotonin 2A receptors in the D-amphetamine-induced release of dopamine: comparison with previous data on alpha1b-adrenergic receptors</article-title>. <source>J. Neurochem.</source> <volume>91</volume>, <fpage>318</fpage>&#x02013;<lpage>326</lpage>.<pub-id pub-id-type="doi">10.1111/j.1471-4159.2004.02714.x</pub-id><pub-id pub-id-type="pmid">15447665</pub-id></citation></ref>
<ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berg</surname> <given-names>K. A.</given-names></name> <name><surname>Clarke</surname> <given-names>W. P.</given-names></name> <name><surname>Chen</surname> <given-names>Y.</given-names></name> <name><surname>Ebersole</surname> <given-names>B. J.</given-names></name> <name><surname>McKay</surname> <given-names>R. D. G.</given-names></name> <name><surname>Maayani</surname> <given-names>S.</given-names></name></person-group> (<year>1994</year>). <article-title>5-hydroxytryptamine type 2A receptors regulate cyclic AMP accumulation in a neuronal cell line by protein kinase C-dependent and calcium/calmodulin-dependent mechanisms</article-title>. <source>Mol. Pharmacol.</source> <volume>45</volume>, <fpage>826</fpage>&#x02013;<lpage>836</lpage>.<pub-id pub-id-type="pmid">8190100</pub-id></citation></ref>
<ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berg</surname> <given-names>K. A.</given-names></name> <name><surname>Harvey</surname> <given-names>J. A.</given-names></name> <name><surname>Spampinato</surname> <given-names>U.</given-names></name> <name><surname>Clarke</surname> <given-names>W. P.</given-names></name></person-group> (<year>2005</year>). <article-title>Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors</article-title>. <source>Trends Pharmacol. Sci.</source> <volume>26</volume>, <fpage>625</fpage>&#x02013;<lpage>630</lpage>.<pub-id pub-id-type="doi">10.1016/j.tips.2005.10.008</pub-id><pub-id pub-id-type="pmid">16269190</pub-id></citation></ref>
<ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bolanos</surname> <given-names>C. A.</given-names></name> <name><surname>Perrotti</surname> <given-names>L. I.</given-names></name> <name><surname>Edwards</surname> <given-names>S.</given-names></name> <name><surname>Eisch</surname> <given-names>A. J.</given-names></name> <name><surname>Barrot</surname> <given-names>M.</given-names></name> <name><surname>Olson</surname> <given-names>V. G.</given-names></name> <etal/></person-group> (<year>2003</year>). <article-title>Phospholipase Cgamma in distinct regions of the ventral tegmental area differentially modulates mood-related behaviors</article-title>. <source>J. Neurosci.</source> <volume>23</volume>, <fpage>7569</fpage>&#x02013;<lpage>7576</lpage>.<pub-id pub-id-type="pmid">12930795</pub-id></citation></ref>
<ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonaccorso</surname> <given-names>S.</given-names></name> <name><surname>Meltzer</surname> <given-names>H. Y.</given-names></name> <name><surname>Li</surname> <given-names>Z.</given-names></name> <name><surname>Dai</surname> <given-names>J.</given-names></name> <name><surname>Alboszta</surname> <given-names>A. R.</given-names></name> <name><surname>Ichikawa</surname> <given-names>J.</given-names></name></person-group> (<year>2002</year>). <article-title>SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens</article-title>. <source>Neuropsychopharmacology</source> <volume>27</volume>, <fpage>430</fpage>&#x02013;<lpage>441</lpage>.<pub-id pub-id-type="doi">10.1016/S0893-133X(02)00311-1</pub-id><pub-id pub-id-type="pmid">12225700</pub-id></citation></ref>
<ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Broderick</surname> <given-names>P. A.</given-names></name> <name><surname>Olabisi</surname> <given-names>O. A.</given-names></name> <name><surname>Rahni</surname> <given-names>D. N.</given-names></name> <name><surname>Zhou</surname> <given-names>Y.</given-names></name></person-group> (<year>2004</year>). <article-title>Cocaine acts on accumbens monoamines and locomotor behavior via a 5-HT2A/2C receptor mechanism as shown by ketanserin: 24-h follow-up studies</article-title>. <source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source> <volume>28</volume>, <fpage>547</fpage>&#x02013;<lpage>557</lpage>.<pub-id pub-id-type="doi">10.1016/j.pnpbp.2004.01.007</pub-id><pub-id pub-id-type="pmid">15093963</pub-id></citation></ref>
<ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Browning</surname> <given-names>J. L.</given-names></name> <name><surname>Patel</surname> <given-names>T.</given-names></name> <name><surname>Brandt</surname> <given-names>P. C.</given-names></name> <name><surname>Young</surname> <given-names>K. A.</given-names></name> <name><surname>Holcomb</surname> <given-names>L. A.</given-names></name> <name><surname>Hicks</surname> <given-names>P. B.</given-names></name></person-group> (<year>2005</year>). <article-title>Clozapine and the mitogen-activated protein kinase signal transduction pathway: implications for antipsychotic actions</article-title>. <source>Biol. Psychiatry</source> <volume>57</volume>, <fpage>617</fpage>&#x02013;<lpage>623</lpage>.<pub-id pub-id-type="doi">10.1016/j.biopsych.2004.12.002</pub-id><pub-id pub-id-type="pmid">15780848</pub-id></citation></ref>
<ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bubar</surname> <given-names>M. J.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>2007</year>). <article-title>Distribution of serotonin 5-HT2C receptors in the ventral tegmental area</article-title>. <source>Neuroscience</source> <volume>146</volume>, <fpage>286</fpage>&#x02013;<lpage>277</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuroscience.2006.12.071</pub-id><pub-id pub-id-type="pmid">17367945</pub-id></citation></ref>
<ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bubar</surname> <given-names>M. J.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>2008</year>). <article-title>Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse</article-title>. <source>Prog. Brain Res.</source> <volume>172</volume>, <fpage>319</fpage>&#x02013;<lpage>346</lpage>.<pub-id pub-id-type="doi">10.1016/S0079-6123(08)00916-3</pub-id><pub-id pub-id-type="pmid">18772040</pub-id></citation></ref>
<ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bubar</surname> <given-names>M. J.</given-names></name> <name><surname>McMahon</surname> <given-names>L. R.</given-names></name> <name><surname>De Deurwaerdere</surname> <given-names>P.</given-names></name> <name><surname>Spampinato</surname> <given-names>U.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>2003</year>). <article-title>Selective serotonin reuptake inhibitors enhance cocaine-induced locomotor activity and dopamine release in the nucleus accumbens</article-title>. <source>Neuropharmacology</source> <volume>44</volume>, <fpage>342</fpage>&#x02013;<lpage>353</lpage>.<pub-id pub-id-type="doi">10.1016/S0028-3908(02)00381-7</pub-id><pub-id pub-id-type="pmid">12604093</pub-id></citation></ref>
<ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bubar</surname> <given-names>M. J.</given-names></name> <name><surname>Seitz</surname> <given-names>P. K.</given-names></name> <name><surname>Thomas</surname> <given-names>M. L.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>2005</year>). <article-title>Validation of a selective serotonin 5-HT(2C) receptor antibody for utilization in fluorescence immunohistochemistry studies</article-title>. <source>Brain Res.</source> <volume>1063</volume>, <fpage>105</fpage>&#x02013;<lpage>113</lpage>.<pub-id pub-id-type="doi">10.1016/j.brainres.2005.09.050</pub-id><pub-id pub-id-type="pmid">16274677</pub-id></citation></ref>
<ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bubar</surname> <given-names>M. J.</given-names></name> <name><surname>Stutz</surname> <given-names>S. J.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>2011</year>). <article-title>5-HT(2C) receptors localize to dopamine and GABA neurons in the rat mesoaccumbens pathway</article-title>. <source>PLoS ONE</source> <volume>6</volume>:<fpage>e20508</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pone.0020508</pub-id></citation></ref>
<ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Callahan</surname> <given-names>P. M.</given-names></name> <name><surname>De La Garza</surname> <given-names>R.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>1994</year>). <article-title>Discriminative stimulus properties of cocaine: Modification by dopamine D1 receptors in nucleus accumbens</article-title>. <source>Psychopharmacology (Berl.)</source> <volume>115</volume>, <fpage>110</fpage>&#x02013;<lpage>114</lpage>.<pub-id pub-id-type="doi">10.1007/BF02244759</pub-id><pub-id pub-id-type="pmid">7862881</pub-id></citation></ref>
<ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carlezon</surname> <given-names>W. A.</given-names> <suffix>Jr.</suffix></name> <name><surname>Boundy</surname> <given-names>V. A.</given-names></name> <name><surname>Haile</surname> <given-names>C. N.</given-names></name> <name><surname>Lane</surname> <given-names>S. B.</given-names></name> <name><surname>Kalb</surname> <given-names>R. G.</given-names></name> <name><surname>Neve</surname> <given-names>R. L.</given-names></name> <etal/></person-group> (<year>1997</year>). <article-title>Sensitization to morphine induced by viral-mediated gene transfer</article-title>. <source>Science</source> <volume>277</volume>, <fpage>812</fpage>&#x02013;<lpage>814</lpage>.<pub-id pub-id-type="doi">10.1126/science.277.5327.812</pub-id><pub-id pub-id-type="pmid">9242609</pub-id></citation></ref>
<ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chamberlin</surname> <given-names>N. L.</given-names></name> <name><surname>Du</surname> <given-names>B.</given-names></name> <name><surname>de</surname> <given-names>L. S.</given-names></name> <name><surname>Saper</surname> <given-names>C. B.</given-names></name></person-group> (<year>1998</year>). <article-title>Recombinant adeno-associated virus vector: use for transgene expression and anterograde tract tracing in the CNS</article-title>. <source>Brain Res.</source> <volume>793</volume>, <fpage>169</fpage>&#x02013;<lpage>175</lpage>.<pub-id pub-id-type="doi">10.1016/S0006-8993(98)00169-3</pub-id><pub-id pub-id-type="pmid">9630611</pub-id></citation></ref>
<ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>N.-H.</given-names></name> <name><surname>Reith</surname> <given-names>M. E. A.</given-names></name></person-group> (<year>1994</year>). <article-title>Effects of locally applied cocaine, lidocaine, and various uptake blockers on monoamine transmission in the ventral tegmental area of freely moving rats: a microdialysis study on monoamine interrelationships</article-title>. <source>J. Neurochem.</source> <volume>63</volume>, <fpage>1701</fpage>&#x02013;<lpage>1713</lpage>.<pub-id pub-id-type="doi">10.1046/j.1471-4159.1994.63051701.x</pub-id><pub-id pub-id-type="pmid">7931325</pub-id></citation></ref>
<ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cornea-Hebert</surname> <given-names>V.</given-names></name> <name><surname>Riad</surname> <given-names>M.</given-names></name> <name><surname>Wu</surname> <given-names>C.</given-names></name> <name><surname>Singh</surname> <given-names>S. K.</given-names></name> <name><surname>Descarries</surname> <given-names>L.</given-names></name></person-group> (<year>1999</year>). <article-title>Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat</article-title>. <source>J. Comp. Neurol.</source> <volume>409</volume>, <fpage>187</fpage>&#x02013;<lpage>209</lpage>.<pub-id pub-id-type="doi">10.1002/(SICI)1096-9861(19990628)409:2&#x0003C;187::AID-CNE2&#x0003E;3.0.CO;2-P</pub-id><pub-id pub-id-type="pmid">10379914</pub-id></citation></ref>
<ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cornea-Hebert</surname> <given-names>V.</given-names></name> <name><surname>Watkins</surname> <given-names>K. C.</given-names></name> <name><surname>Roth</surname> <given-names>B. L.</given-names></name> <name><surname>Kroeze</surname> <given-names>W. K.</given-names></name> <name><surname>Gaudreau</surname> <given-names>P.</given-names></name> <name><surname>Leclerc</surname> <given-names>N.</given-names></name> <etal/></person-group> (<year>2002</year>). <article-title>Similar ultrastructural distribution of the 5-HT(2A) serotonin receptor and microtubule-associated protein MAP1A in cortical dendrites of adult rat</article-title>. <source>Neuroscience</source> <volume>113</volume>, <fpage>23</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1016/S0306-4522(02)00146-X</pub-id><pub-id pub-id-type="pmid">12123681</pub-id></citation></ref>
<ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Couzin</surname> <given-names>J.</given-names></name></person-group> (<year>2006</year>). <article-title>Scientific publishing. Don&#x02019;t pretty up that picture just yet</article-title>. <source>Science</source> <volume>314</volume>, <fpage>1866</fpage>&#x02013;<lpage>1868</lpage>.<pub-id pub-id-type="doi">10.1126/science.314.5804.1371a</pub-id><pub-id pub-id-type="pmid">17185580</pub-id></citation></ref>
<ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname> <given-names>K. A.</given-names></name> <name><surname>Anastasio</surname> <given-names>N. C.</given-names></name> <name><surname>Fox</surname> <given-names>R. G.</given-names></name> <name><surname>Stutz</surname> <given-names>S. J.</given-names></name> <name><surname>Bubar</surname> <given-names>M. J.</given-names></name> <name><surname>Swinford</surname> <given-names>S. E.</given-names></name> <etal/></person-group> (<year>2013</year>). <article-title>Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction</article-title>. <source>ACS Chem. Neurosci.</source> <volume>4</volume>, <fpage>110</fpage>&#x02013;<lpage>121</lpage>.<pub-id pub-id-type="doi">10.1021/cn300072u</pub-id><pub-id pub-id-type="pmid">23336050</pub-id></citation></ref>
<ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Deurwaerdere</surname> <given-names>P.</given-names></name> <name><surname>Spampinato</surname> <given-names>U.</given-names></name></person-group> (<year>1999</year>). <article-title>Role of serotonin(2A) and serotonin(2B/2C) receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation</article-title>. <source>J. Neurochem.</source> <volume>73</volume>, <fpage>1033</fpage>&#x02013;<lpage>1042</lpage>.<pub-id pub-id-type="doi">10.1046/j.1471-4159.1999.0731033.x</pub-id><pub-id pub-id-type="pmid">10461892</pub-id></citation></ref>
<ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De La Garza</surname> <given-names>R.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>2000</year>). <article-title>The effects of the 5-HT1A agonist 8-hydroxy-2(di-n-propylamino)tetralin on spontaneous activity and cocaine-induced hyperactivity and behavioral sensitization</article-title>. <source>J. Pharmacol. Exp. Ther.</source> <volume>292</volume>, <fpage>610</fpage>&#x02013;<lpage>617</lpage>.<pub-id pub-id-type="pmid">10640298</pub-id></citation></ref>
<ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delfs</surname> <given-names>J. M.</given-names></name> <name><surname>Schreiber</surname> <given-names>L.</given-names></name> <name><surname>Kelley</surname> <given-names>A. E.</given-names></name></person-group> (<year>1990</year>). <article-title>Microinjection of cocaine into the nucleus accumbens elicits locomotor activation in the rat</article-title>. <source>J. Neurosci.</source> <volume>10</volume>, <fpage>303</fpage>&#x02013;<lpage>310</lpage>.<pub-id pub-id-type="pmid">2299396</pub-id></citation></ref>
<ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Giovanni</surname> <given-names>G.</given-names></name> <name><surname>De Deurwaerdere</surname> <given-names>P.</given-names></name> <name><surname>Di Mascio</surname> <given-names>M.</given-names></name> <name><surname>Di Matteo</surname> <given-names>V.</given-names></name> <name><surname>Esposito</surname> <given-names>E.</given-names></name> <name><surname>Spampinato</surname> <given-names>U.</given-names></name></person-group> (<year>1999</year>). <article-title>Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study</article-title>. <source>Neuroscience</source> <volume>91</volume>, <fpage>587</fpage>&#x02013;<lpage>597</lpage>.<pub-id pub-id-type="doi">10.1016/S0306-4522(98)00655-1</pub-id><pub-id pub-id-type="pmid">10366016</pub-id></citation></ref>
<ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doherty</surname> <given-names>M. D.</given-names></name> <name><surname>Pickel</surname> <given-names>V. M.</given-names></name></person-group> (<year>2000</year>). <article-title>Ultrastructural localization of the 5-HT2A receptor in dopaminergic neurons in the ventral tegmental area</article-title>. <source>Brain Res.</source> <volume>864</volume>, <fpage>176</fpage>&#x02013;<lpage>185</lpage>.<pub-id pub-id-type="doi">10.1016/S0006-8993(00)02062-X</pub-id><pub-id pub-id-type="pmid">10802024</pub-id></citation></ref>
<ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edry</surname> <given-names>E.</given-names></name> <name><surname>Lamprecht</surname> <given-names>R.</given-names></name> <name><surname>Wagner</surname> <given-names>S.</given-names></name> <name><surname>Rosenblum</surname> <given-names>K.</given-names></name></person-group> (<year>2011</year>). <article-title>Virally mediated gene manipulation in the adult CNS</article-title>. <source>Front. Mol. Neurosci.</source> <volume>4</volume>:<fpage>57</fpage>.<pub-id pub-id-type="doi">10.3389/fnmol.2011.00057</pub-id></citation></ref>
<ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ehrengruber</surname> <given-names>M. U.</given-names></name> <name><surname>Hennou</surname> <given-names>S.</given-names></name> <name><surname>Bueler</surname> <given-names>H.</given-names></name> <name><surname>Naim</surname> <given-names>H. Y.</given-names></name> <name><surname>Deglon</surname> <given-names>N.</given-names></name> <name><surname>Lundstrom</surname> <given-names>K.</given-names></name></person-group> (<year>2001</year>). <article-title>Gene transfer into neurons from hippocampal slices: comparison of recombinant Semliki forest virus, adenovirus, adeno-associated virus, lentivirus, and measles virus</article-title>. <source>Mol. Cell Neurosci.</source> <volume>17</volume>, <fpage>855</fpage>&#x02013;<lpage>871</lpage>.<pub-id pub-id-type="doi">10.1006/mcne.2001.0982</pub-id><pub-id pub-id-type="pmid">11358483</pub-id></citation></ref>
<ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Filip</surname> <given-names>M.</given-names></name> <name><surname>Alenina</surname> <given-names>N.</given-names></name> <name><surname>Bader</surname> <given-names>M.</given-names></name> <name><surname>Przegalinski</surname> <given-names>E.</given-names></name></person-group> (<year>2010</year>). <article-title>Behavioral evidence for the significance of serotoninergic (5-HT) receptors in cocaine addiction</article-title>. <source>Addict. Biol.</source> <volume>15</volume>, <fpage>227</fpage>&#x02013;<lpage>249</lpage>.<pub-id pub-id-type="doi">10.1111/j.1369-1600.2010.00214.x</pub-id><pub-id pub-id-type="pmid">20456287</pub-id></citation></ref>
<ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Filip</surname> <given-names>M.</given-names></name> <name><surname>Bubar</surname> <given-names>M. J.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Contribution of serotonin (5-hydroxytryptamine; 5-HT) 5-HT2 receptor subtypes to the hyperlocomotor effects of cocaine: acute and chronic pharmacological analyses</article-title>. <source>J. Pharmacol. Exp. Ther.</source> <volume>310</volume>, <fpage>1246</fpage>&#x02013;<lpage>1254</lpage>.<pub-id pub-id-type="doi">10.1124/jpet.104.068841</pub-id><pub-id pub-id-type="pmid">15131246</pub-id></citation></ref>
<ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Filip</surname> <given-names>M.</given-names></name> <name><surname>Bubar</surname> <given-names>M. J.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Contribution of serotonin (5-HT) 5-HT2 receptor subtypes to the discriminative stimulus effects of cocaine in rats</article-title>. <source>Psychopharmacology (Berl.)</source> <volume>183</volume>, <fpage>482</fpage>&#x02013;<lpage>489</lpage>.<pub-id pub-id-type="doi">10.1007/s00213-005-0197-y</pub-id><pub-id pub-id-type="pmid">16261316</pub-id></citation></ref>
<ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Filip</surname> <given-names>M.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>2002</year>). <article-title>Serotonin 5-HT(2C) receptors in nucleus accumbens regulate expression of the hyperlocomotive and discriminative stimulus effects of cocaine</article-title>. <source>Pharmacol. Biochem. Behav.</source> <volume>71</volume>, <fpage>745</fpage>&#x02013;<lpage>756</lpage>.<pub-id pub-id-type="doi">10.1016/S0091-3057(01)00741-9</pub-id><pub-id pub-id-type="pmid">11888566</pub-id></citation></ref>
<ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname> <given-names>P. J.</given-names></name> <name><surname>Grottick</surname> <given-names>A. J.</given-names></name> <name><surname>Higgins</surname> <given-names>G. A.</given-names></name></person-group> (<year>2002</year>). <article-title>Differential effects of the 5-HT2A receptor antagonist M100,907 and the 5-HT2C receptor antagonist SB242,084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding</article-title>. <source>Neuropsychopharmacology</source> <volume>27</volume>, <fpage>576</fpage>&#x02013;<lpage>586</lpage>.<pub-id pub-id-type="pmid">12377394</pub-id></citation></ref>
<ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname> <given-names>P. J.</given-names></name> <name><surname>Rizos</surname> <given-names>Z.</given-names></name> <name><surname>Noble</surname> <given-names>K.</given-names></name> <name><surname>Higgins</surname> <given-names>G. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Impulsive action induced by amphetamine, cocaine and MK801 is reduced by 5-HT(2C) receptor stimulation and 5-HT(2A) receptor blockade</article-title>. <source>Neuropharmacology</source> <volume>61</volume>, <fpage>468</fpage>&#x02013;<lpage>477</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.02.025</pub-id><pub-id pub-id-type="pmid">21402085</pub-id></citation></ref>
<ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garlow</surname> <given-names>S. J.</given-names></name> <name><surname>Morilak</surname> <given-names>D. A.</given-names></name> <name><surname>Dean</surname> <given-names>R. R.</given-names></name> <name><surname>Roth</surname> <given-names>B. L.</given-names></name> <name><surname>Ciaranello</surname> <given-names>R. D.</given-names></name></person-group> (<year>1993</year>). <article-title>Production and characterization of a specific 5-HT2 receptor antibody</article-title>. <source>Brain Res.</source> <volume>615</volume>, <fpage>113</fpage>&#x02013;<lpage>120</lpage>.<pub-id pub-id-type="doi">10.1016/0006-8993(93)91121-8</pub-id><pub-id pub-id-type="pmid">7689908</pub-id></citation></ref>
<ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halliday</surname> <given-names>G. M.</given-names></name> <name><surname>Tork</surname> <given-names>I.</given-names></name></person-group> (<year>1989</year>). <article-title>Serotonin-Like immunoreactive cells and fibres in the rat ventromedial mesencephalic tegmentum</article-title>. <source>Brain Res. Bull.</source> <volume>22</volume>, <fpage>725</fpage>&#x02013;<lpage>735</lpage>.<pub-id pub-id-type="doi">10.1016/0361-9230(89)90092-0</pub-id><pub-id pub-id-type="pmid">2736398</pub-id></citation></ref>
<ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herges</surname> <given-names>S.</given-names></name> <name><surname>Taylor</surname> <given-names>D. A.</given-names></name></person-group> (<year>1998</year>). <article-title>Involvement of serotonin in the modulation of cocaine-induced locomotor activity in the rat</article-title>. <source>Pharmacol. Biochem. Behav.</source> <volume>59</volume>, <fpage>595</fpage>&#x02013;<lpage>611</lpage>.<pub-id pub-id-type="doi">10.1016/S0091-3057(97)00473-5</pub-id><pub-id pub-id-type="pmid">9512061</pub-id></citation></ref>
<ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herin</surname> <given-names>D. V.</given-names></name> <name><surname>Liu</surname> <given-names>S.</given-names></name> <name><surname>Ullrich</surname> <given-names>T.</given-names></name> <name><surname>Rice</surname> <given-names>K. C.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>2005</year>). <article-title>Role of the serotonin 5-HT2A receptor in the hyperlocomotive and hyperthermic effects of (&#x0002B;)-3,4-methylenedioxymethamphetamine</article-title>. <source>Psychopharmacology (Berl.)</source> <volume>178</volume>, <fpage>505</fpage>&#x02013;<lpage>513</lpage>.<pub-id pub-id-type="doi">10.1007/s00213-004-2030-4</pub-id><pub-id pub-id-type="pmid">15765263</pub-id></citation></ref>
<ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hillman</surname> <given-names>G.</given-names></name></person-group> (<year>1984</year>). <article-title>Quantitation of acetylcholinesterase in frozen tissue sections by computer image analysis</article-title>. <source>Pharmacologist</source> <volume>26</volume>, <fpage>225</fpage>.</citation></ref>
<ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoyer</surname> <given-names>D.</given-names></name> <name><surname>Hannon</surname> <given-names>J. P.</given-names></name> <name><surname>Martin</surname> <given-names>G. R.</given-names></name></person-group> (<year>2002</year>). <article-title>Molecular, pharmacological and functional diversity of 5-HT receptors</article-title>. <source>Pharmacol. Biochem. Behav.</source> <volume>71</volume>, <fpage>533</fpage>&#x02013;<lpage>554</lpage>.<pub-id pub-id-type="doi">10.1016/S0091-3057(01)00746-8</pub-id><pub-id pub-id-type="pmid">11888546</pub-id></citation></ref>
<ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ikemoto</surname> <given-names>K.</given-names></name> <name><surname>Nishimura</surname> <given-names>A.</given-names></name> <name><surname>Okado</surname> <given-names>N.</given-names></name> <name><surname>Mikuni</surname> <given-names>M.</given-names></name> <name><surname>Nishi</surname> <given-names>K.</given-names></name> <name><surname>Nagatsu</surname> <given-names>I.</given-names></name></person-group> (<year>2000</year>). <article-title>Human midbrain dopamine neurons express serotonin 2A receptor: an immunohistochemical demonstration</article-title>. <source>Brain Res.</source> <volume>853</volume>, <fpage>377</fpage>&#x02013;<lpage>380</lpage>.<pub-id pub-id-type="doi">10.1016/S0006-8993(99)02237-4</pub-id><pub-id pub-id-type="pmid">10640637</pub-id></citation></ref>
<ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ikemoto</surname> <given-names>S.</given-names></name></person-group> (<year>2007</year>). <article-title>Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex</article-title>. <source>Brain Res. Rev.</source> <volume>56</volume>, <fpage>27</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="doi">10.1016/j.brainresrev.2007.05.004</pub-id><pub-id pub-id-type="pmid">17574681</pub-id></citation></ref>
<ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jansson</surname> <given-names>A.</given-names></name> <name><surname>Tinner</surname> <given-names>B.</given-names></name> <name><surname>Bancila</surname> <given-names>M.</given-names></name> <name><surname>Verge</surname> <given-names>D.</given-names></name> <name><surname>Steinbusch</surname> <given-names>H. W.</given-names></name> <name><surname>Agnati</surname> <given-names>L. F.</given-names></name> <etal/></person-group> (<year>2001</year>). <article-title>Relationships of 5-hydroxytryptamine immunoreactive terminal-like varicosities to 5-hydroxytryptamine-2A receptor-immunoreactive neuronal processes in the rat forebrain</article-title>. <source>J. Chem. Neuroanat.</source> <volume>22</volume>, <fpage>185</fpage>&#x02013;<lpage>203</lpage>.<pub-id pub-id-type="doi">10.1016/S0891-0618(01)00133-8</pub-id><pub-id pub-id-type="pmid">11522440</pub-id></citation></ref>
<ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname> <given-names>S. W.</given-names></name> <name><surname>North</surname> <given-names>R. A.</given-names></name></person-group> (<year>1992</year>). <article-title>Two types of neurone in the rat ventral tegmental area and their synaptic inputs</article-title>. <source>J. Physiol. (Lond.)</source> <volume>450</volume>, <fpage>455</fpage>&#x02013;<lpage>468</lpage>.<pub-id pub-id-type="pmid">1331427</pub-id></citation></ref>
<ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaplitt</surname> <given-names>M. G.</given-names></name> <name><surname>Feigin</surname> <given-names>A.</given-names></name> <name><surname>Tang</surname> <given-names>C.</given-names></name> <name><surname>Fitzsimons</surname> <given-names>H. L.</given-names></name> <name><surname>Mattis</surname> <given-names>P.</given-names></name> <name><surname>Lawlor</surname> <given-names>P. A.</given-names></name> <etal/></person-group> (<year>2007</year>). <article-title>Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson&#x02019;s disease: an open label, phase I trial</article-title>. <source>Lancet</source> <volume>369</volume>, <fpage>2097</fpage>&#x02013;<lpage>2105</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(07)60982-9</pub-id><pub-id pub-id-type="pmid">17586305</pub-id></citation></ref>
<ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname> <given-names>P. H.</given-names></name> <name><surname>Iversen</surname> <given-names>S. D.</given-names></name></person-group> (<year>1976</year>). <article-title>Selective 6-OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats</article-title>. <source>Eur. J. Pharmacol.</source> <volume>40</volume>, <fpage>45</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="doi">10.1016/0014-2999(76)90352-6</pub-id><pub-id pub-id-type="pmid">1033072</pub-id></citation></ref>
<ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koe</surname> <given-names>B. K.</given-names></name></person-group> (<year>1976</year>). <article-title>Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain</article-title>. <source>J. Pharmacol. Exp. Ther.</source> <volume>199</volume>, <fpage>649</fpage>&#x02013;<lpage>661</lpage>.<pub-id pub-id-type="pmid">994022</pub-id></citation></ref>
<ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuroki</surname> <given-names>T.</given-names></name> <name><surname>Meltzer</surname> <given-names>H. Y.</given-names></name> <name><surname>Ichikawa</surname> <given-names>J.</given-names></name></person-group> (<year>2003</year>). <article-title>5-HT 2A receptor stimulation by DOI, a 5-HT 2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens</article-title>. <source>Brain Res.</source> <volume>972</volume>, <fpage>216</fpage>&#x02013;<lpage>221</lpage>.<pub-id pub-id-type="doi">10.1016/S0006-8993(03)02516-2</pub-id><pub-id pub-id-type="pmid">12711095</pub-id></citation></ref>
<ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Landgraf</surname> <given-names>R.</given-names></name> <name><surname>Frank</surname> <given-names>E.</given-names></name> <name><surname>Aldag</surname> <given-names>J. M.</given-names></name> <name><surname>Neumann</surname> <given-names>I. D.</given-names></name> <name><surname>Sharer</surname> <given-names>C. A.</given-names></name> <name><surname>Ren</surname> <given-names>X.</given-names></name> <etal/></person-group> (<year>2003</year>). <article-title>Viral vector-mediated gene transfer of the vole V1a vasopressin receptor in the rat septum: improved social discrimination and active social behaviour</article-title>. <source>Eur. J. Neurosci.</source> <volume>18</volume>, <fpage>403</fpage>&#x02013;<lpage>411</lpage>.<pub-id pub-id-type="doi">10.1046/j.1460-9568.2003.02750.x</pub-id><pub-id pub-id-type="pmid">12887422</pub-id></citation></ref>
<ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leysen</surname> <given-names>J. E.</given-names></name></person-group> (<year>2004</year>). <article-title>5-HT2 receptors</article-title>. <source>Curr. Drug Target CNS. Neurol. Disord.</source> <volume>3</volume>, <fpage>11</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="doi">10.2174/1568007043482598</pub-id></citation></ref>
<ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>S.</given-names></name> <name><surname>Bubar</surname> <given-names>M. J.</given-names></name> <name><surname>Lanfranco</surname> <given-names>M. F.</given-names></name> <name><surname>Hillman</surname> <given-names>G. R.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>2007</year>). <article-title>Serotonin(2C) receptor localization in GABA neurons of the rat medial prefrontal cortex: implications for understanding the neurobiology of addiction</article-title>. <source>Neuroscience</source> <volume>146</volume>, <fpage>1667</fpage>&#x02013;<lpage>1688</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuroscience.2007.02.056</pub-id></citation></ref>
<ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>S.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Serotonin(2C) receptors (5-HT(2C)R) control expression of cocaine-induced conditioned hyperactivity</article-title>. <source>Drug Alcohol Depend.</source> <volume>81</volume>, <fpage>275</fpage>&#x02013;<lpage>282</lpage>.<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2005.07.007</pub-id><pub-id pub-id-type="pmid">16146672</pub-id></citation></ref>
<ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname> <given-names>W. D.</given-names></name> <name><surname>Qu</surname> <given-names>G.</given-names></name> <name><surname>Sferra</surname> <given-names>T. J.</given-names></name> <name><surname>Clark</surname> <given-names>R.</given-names></name> <name><surname>Chen</surname> <given-names>R.</given-names></name> <name><surname>Johnson</surname> <given-names>P. R.</given-names></name></person-group> (<year>1999</year>). <article-title>Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression</article-title>. <source>Hum. Gene Ther.</source> <volume>10</volume>, <fpage>201</fpage>&#x02013;<lpage>213</lpage>.<pub-id pub-id-type="doi">10.1089/10430349950018995</pub-id><pub-id pub-id-type="pmid">10022545</pub-id></citation></ref>
<ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCown</surname> <given-names>T. J.</given-names></name> <name><surname>Xiao</surname> <given-names>X.</given-names></name> <name><surname>Li</surname> <given-names>J.</given-names></name> <name><surname>Breese</surname> <given-names>G. R.</given-names></name> <name><surname>Samulski</surname> <given-names>R. J.</given-names></name></person-group> (<year>1996</year>). <article-title>Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector</article-title>. <source>Brain Res.</source> <volume>713</volume>, <fpage>99</fpage>&#x02013;<lpage>107</lpage>.<pub-id pub-id-type="doi">10.1016/0006-8993(95)01488-8</pub-id><pub-id pub-id-type="pmid">8724980</pub-id></citation></ref>
<ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCreary</surname> <given-names>A. C.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>1999</year>). <article-title>The effects of the 5-HT2C/2B antagonist SB 206553 on cocaine-induced locomotor activity</article-title>. <source>Neuropsychopharmacology</source> <volume>20</volume>, <fpage>556</fpage>&#x02013;<lpage>564</lpage>.<pub-id pub-id-type="doi">10.1016/S0893-133X(98)00087-6</pub-id><pub-id pub-id-type="pmid">10327425</pub-id></citation></ref>
<ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McMahon</surname> <given-names>L. R.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>2001</year>). <article-title>Antagonism of 5-hydroxytryptamine(2a) receptors attenuates the behavioral effects of cocaine in rats</article-title>. <source>J. Pharmacol. Exp. Ther.</source> <volume>297</volume>, <fpage>357</fpage>&#x02013;<lpage>363</lpage>.<pub-id pub-id-type="pmid">11259563</pub-id></citation></ref>
<ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McMahon</surname> <given-names>L. R.</given-names></name> <name><surname>Filip</surname> <given-names>M.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>2001</year>). <article-title>Differential regulation of the mesoaccumbens circuit by serotonin 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors</article-title>. <source>J. Neurosci.</source> <volume>21</volume>, <fpage>7781</fpage>&#x02013;<lpage>7787</lpage>.<pub-id pub-id-type="pmid">11567068</pub-id></citation></ref>
<ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miner</surname> <given-names>L. A.</given-names></name> <name><surname>Backstrom</surname> <given-names>J. R.</given-names></name> <name><surname>Sanders-Bush</surname> <given-names>E.</given-names></name> <name><surname>Sesack</surname> <given-names>S. R.</given-names></name></person-group> (<year>2003</year>). <article-title>Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex</article-title>. <source>Neuroscience</source> <volume>116</volume>, <fpage>107</fpage>&#x02013;<lpage>117</lpage>.<pub-id pub-id-type="doi">10.1016/S0306-4522(02)00580-8</pub-id><pub-id pub-id-type="pmid">12535944</pub-id></citation></ref>
<ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miner</surname> <given-names>L. H.</given-names></name> <name><surname>Schroeter</surname> <given-names>S.</given-names></name> <name><surname>Blakely</surname> <given-names>R. D.</given-names></name> <name><surname>Sesack</surname> <given-names>S. R.</given-names></name></person-group> (<year>2000</year>). <article-title>Ultrastructural localization of the serotonin transporter in superficial and deep layers of the rat prelimbic prefrontal cortex and its spatial relationship to dopamine terminals</article-title>. <source>J. Comp. Neurol.</source> <volume>427</volume>, <fpage>220</fpage>&#x02013;<lpage>234</lpage>.<pub-id pub-id-type="doi">10.1002/1096-9861(20001113)427:2&#x0003C;220::AID-CNE5&#x0003E;3.0.CO;2-P</pub-id><pub-id pub-id-type="pmid">11054690</pub-id></citation></ref>
<ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname> <given-names>C. P.</given-names></name> <name><surname>Huston</surname> <given-names>J. P.</given-names></name></person-group> (<year>2006</year>). <article-title>Determining the region-specific contributions of 5-HT receptors to the psychostimulant effects of cocaine</article-title>. <source>Trends Pharmacol. Sci.</source> <volume>27</volume>, <fpage>105</fpage>&#x02013;<lpage>112</lpage>.<pub-id pub-id-type="doi">10.1002/jps.3080270207</pub-id><pub-id pub-id-type="pmid">16406129</pub-id></citation></ref>
<ref id="B64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nic Dhonnchadha</surname> <given-names>B. A.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>2008</year>). <article-title>Serotonergic mechanisms in addiction-related memories</article-title>. <source>Behav. Brain Res.</source> <volume>195</volume>, <fpage>39</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbr.2008.06.026</pub-id><pub-id pub-id-type="pmid">18639587</pub-id></citation></ref>
<ref id="B65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nic Dhonnchadha</surname> <given-names>B. A.</given-names></name> <name><surname>Fox</surname> <given-names>R. G.</given-names></name> <name><surname>Stutz</surname> <given-names>S. J.</given-names></name> <name><surname>Rice</surname> <given-names>K. C.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>2009</year>). <article-title>Blockade of the serotonin 5-HT2A receptor suppresses cue-evoked reinstatement of cocaine-seeking behavior in a rat self-administration model</article-title>. <source>Behav. Neurosci.</source> <volume>123</volume>, <fpage>382</fpage>&#x02013;<lpage>396</lpage>.<pub-id pub-id-type="doi">10.1037/a0014592</pub-id><pub-id pub-id-type="pmid">19331461</pub-id></citation></ref>
<ref id="B66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nocjar</surname> <given-names>C.</given-names></name> <name><surname>Roth</surname> <given-names>B. L.</given-names></name> <name><surname>Pehek</surname> <given-names>E. A.</given-names></name></person-group> (<year>2002</year>). <article-title>Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group</article-title>. <source>Neuroscience</source> <volume>111</volume>, <fpage>163</fpage>&#x02013;<lpage>176</lpage>.<pub-id pub-id-type="doi">10.1016/S0306-4522(01)00593-0</pub-id><pub-id pub-id-type="pmid">11955720</pub-id></citation></ref>
<ref id="B67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olijslagers</surname> <given-names>J. E.</given-names></name> <name><surname>Werkman</surname> <given-names>T. R.</given-names></name> <name><surname>McCreary</surname> <given-names>A. C.</given-names></name> <name><surname>Siarey</surname> <given-names>R.</given-names></name> <name><surname>Kruse</surname> <given-names>C. G.</given-names></name> <name><surname>Wadman</surname> <given-names>W. J.</given-names></name></person-group> (<year>2004</year>). <article-title>5-HT2 receptors differentially modulate dopamine-mediated auto-inhibition in A9 and A10 midbrain areas of the rat</article-title>. <source>Neuropharmacology</source> <volume>46</volume>, <fpage>504</fpage>&#x02013;<lpage>510</lpage>.<pub-id pub-id-type="doi">10.1016/j.neuropharm.2003.10.003</pub-id><pub-id pub-id-type="pmid">14975674</pub-id></citation></ref>
<ref id="B68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Neill</surname> <given-names>M. F.</given-names></name> <name><surname>Heron-Maxwell</surname> <given-names>C. L.</given-names></name> <name><surname>Shaw</surname> <given-names>G.</given-names></name></person-group> (<year>1999</year>). <article-title>5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB</article-title>. <source>Pharmacol. Biochem. Behav.</source> <volume>63</volume>, <fpage>237</fpage>&#x02013;<lpage>243</lpage>.<pub-id pub-id-type="doi">10.1016/S0091-3057(98)00240-8</pub-id><pub-id pub-id-type="pmid">10371652</pub-id></citation></ref>
<ref id="B69"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Paxinos</surname> <given-names>W.</given-names></name> <name><surname>Watson</surname> <given-names>C.</given-names></name></person-group> (<year>1998</year>). <source>The Rat Brain in Stereotaxic Coordinates</source>, <edition>4th Edn</edition>. <publisher-loc>San Diego, CA</publisher-loc>: <publisher-name>Academic Press</publisher-name>.</citation></ref>
<ref id="B70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peroutka</surname> <given-names>S. J.</given-names></name></person-group> (<year>1986</year>). <article-title>Pharmacological differentiation and characterization of 5-HT1A, 5-HT1B, and 5-HT1C binding sites in rat frontal cortex</article-title>. <source>J. Neurochem.</source> <volume>47</volume>, <fpage>529</fpage>&#x02013;<lpage>540</lpage>.<pub-id pub-id-type="doi">10.1111/j.1471-4159.1986.tb04532.x</pub-id><pub-id pub-id-type="pmid">2942638</pub-id></citation></ref>
<ref id="B71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pessia</surname> <given-names>M.</given-names></name> <name><surname>Jiang</surname> <given-names>Z.-G.</given-names></name> <name><surname>North</surname> <given-names>R. A.</given-names></name> <name><surname>Johnson</surname> <given-names>S. W.</given-names></name></person-group> (<year>1994</year>). <article-title>Actions of 5-hydroxytryptamine on ventral tegmental area neurons of the rat in vitro</article-title>. <source>Brain Res.</source> <volume>654</volume>, <fpage>324</fpage>&#x02013;<lpage>330</lpage>.<pub-id pub-id-type="doi">10.1016/0006-8993(94)90495-2</pub-id><pub-id pub-id-type="pmid">7987681</pub-id></citation></ref>
<ref id="B72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Phillipson</surname> <given-names>O. T.</given-names></name></person-group> (<year>1979</year>). <article-title>The cytoarchitecture of the interfascicular nucleus and ventral tegmental area of Tsai in the rat</article-title>. <source>J. Comp. Neurol.</source> <volume>187</volume>, <fpage>85</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="doi">10.1002/cne.901870107</pub-id><pub-id pub-id-type="pmid">489779</pub-id></citation></ref>
<ref id="B73"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pliakas</surname> <given-names>A. M.</given-names></name> <name><surname>Carlson</surname> <given-names>R. R.</given-names></name> <name><surname>Neve</surname> <given-names>R. L.</given-names></name> <name><surname>Konradi</surname> <given-names>C.</given-names></name> <name><surname>Nestler</surname> <given-names>E. J.</given-names></name> <name><surname>Carlezon</surname> <given-names>W. A.</given-names> <suffix>Jr.</suffix></name></person-group> (<year>2001</year>). <article-title>Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens</article-title>. <source>J. Neurosci.</source> <volume>21</volume>, <fpage>7397</fpage>&#x02013;<lpage>7403</lpage>.<pub-id pub-id-type="pmid">11549750</pub-id></citation></ref>
<ref id="B74"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pockros</surname> <given-names>L. A.</given-names></name> <name><surname>Pentkowski</surname> <given-names>N. S.</given-names></name> <name><surname>Swinford</surname> <given-names>S. E.</given-names></name> <name><surname>Neisewander</surname> <given-names>J. L.</given-names></name></person-group> (<year>2011</year>). <article-title>Blockade of 5-HT2A receptors in the medial prefrontal cortex attenuates reinstatement of cue-elicited cocaine-seeking behavior in rats</article-title>. <source>Psychopharmacology (Berl.)</source> <volume>213</volume>, <fpage>307</fpage>&#x02013;<lpage>320</lpage>.<pub-id pub-id-type="doi">10.1007/s00213-010-2071-9</pub-id><pub-id pub-id-type="pmid">21079923</pub-id></citation></ref>
<ref id="B75"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Pollandt</surname> <given-names>S.W.</given-names></name> <name><surname>Orozco-Cabal</surname> <given-names>L.</given-names></name> <name><surname>Scott</surname> <given-names>M. T.</given-names></name> <name><surname>Liu</surname> <given-names>J.</given-names></name> <name><surname>Krishnan</surname> <given-names>B.</given-names></name> <name><surname>Hillman</surname> <given-names>G. R.</given-names></name> <etal/></person-group> (<year>2005</year>). <source>CRF1/2-Immunoreactivity in the Frontolimbic Circuitry is Increased after Acute and Decreased after Protracted Withdrawal from Repeated Cocaine Administration in Rats</source>. Program No. 682.2, Neuroscience 2005 Abstracts, <publisher-loc>Washington</publisher-loc>: <publisher-name>Society for Neuroscience</publisher-name>, Online.</citation></ref>
<ref id="B76"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname> <given-names>J. D.</given-names></name> <name><surname>Herin</surname> <given-names>D. V.</given-names></name> <name><surname>Frankel</surname> <given-names>P. S.</given-names></name> <name><surname>Thomas</surname> <given-names>M. L.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>2006</year>). <article-title>Chronic treatment with a serotonin(2) receptor (5-HT(2)R) agonist modulates the behavioral and cellular response to (&#x0002B;)-3,4-methylenedioxymethamphetamine [(&#x0002B;)-MDMA]</article-title>. <source>Drug Alcohol Depend.</source> <volume>81</volume>, <fpage>117</fpage>&#x02013;<lpage>127</lpage>.<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2005.06.004</pub-id><pub-id pub-id-type="pmid">16054778</pub-id></citation></ref>
<ref id="B77"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname> <given-names>B. L.</given-names></name> <name><surname>Palvimaki</surname> <given-names>E.-P.</given-names></name> <name><surname>Berry</surname> <given-names>S.</given-names></name> <name><surname>Khan</surname> <given-names>N.</given-names></name> <name><surname>Sachs</surname> <given-names>N.</given-names></name> <name><surname>Uluer</surname> <given-names>A.</given-names></name> <etal/></person-group> (<year>1995</year>). <article-title>5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation</article-title>. <source>J. Pharmacol. Exp. Ther.</source> <volume>275</volume>, <fpage>1638</fpage>&#x02013;<lpage>1646</lpage>.<pub-id pub-id-type="pmid">8531139</pub-id></citation></ref>
<ref id="B78"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rothman</surname> <given-names>R. B.</given-names></name> <name><surname>Baumann</surname> <given-names>M. H.</given-names></name> <name><surname>Savage</surname> <given-names>J. E.</given-names></name> <name><surname>Rauser</surname> <given-names>L.</given-names></name> <name><surname>McBride</surname> <given-names>A.</given-names></name> <name><surname>Hufeisen</surname> <given-names>S. J.</given-names></name> <etal/></person-group> (<year>2000</year>). <article-title>Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications</article-title>. <source>Circulation</source> <volume>102</volume>, <fpage>2836</fpage>&#x02013;<lpage>2841</lpage>.<pub-id pub-id-type="doi">10.1161/01.CIR.102.23.2836</pub-id><pub-id pub-id-type="pmid">11104741</pub-id></citation></ref>
<ref id="B79"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname> <given-names>C. J.</given-names></name> <name><surname>Fadayel</surname> <given-names>G. M.</given-names></name> <name><surname>Sullivan</surname> <given-names>C. K.</given-names></name> <name><surname>Taylor</surname> <given-names>V. L.</given-names></name></person-group> (<year>1992</year>). <article-title>5-HT2 Receptors exert a state-dependent regulation of dopaminergic function: Studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine</article-title>. <source>Eur. J. Pharmacol.</source> <volume>223</volume>, <fpage>65</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1016/0014-2999(92)90819-P</pub-id><pub-id pub-id-type="pmid">1362159</pub-id></citation></ref>
<ref id="B80"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shank</surname> <given-names>E. J.</given-names></name> <name><surname>Seitz</surname> <given-names>P. K.</given-names></name> <name><surname>Bubar</surname> <given-names>M. J.</given-names></name> <name><surname>Stutz</surname> <given-names>S. J.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>2007</year>). <article-title>Selective ablation of GABA neurons in the ventral tegmental area increases spontaneous locomotor activity</article-title>. <source>Behav. Neurosci.</source> <volume>121</volume>, <fpage>1224</fpage>&#x02013;<lpage>1233</lpage>.<pub-id pub-id-type="doi">10.1037/0735-7044.121.6.1224</pub-id><pub-id pub-id-type="pmid">18085876</pub-id></citation></ref>
<ref id="B81"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>St Martin</surname> <given-names>J. L.</given-names></name> <name><surname>Klucken</surname> <given-names>J.</given-names></name> <name><surname>Outeiro</surname> <given-names>T. F.</given-names></name> <name><surname>Nguyen</surname> <given-names>P.</given-names></name> <name><surname>Keller-McGandy</surname> <given-names>C.</given-names></name> <name><surname>Cantuti-Castelvetri</surname> <given-names>I.</given-names></name> <etal/></person-group> (<year>2007</year>). <article-title>Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra</article-title>. <source>J. Neurochem.</source> <volume>100</volume>, <fpage>1449</fpage>&#x02013;<lpage>1457</lpage>.<pub-id pub-id-type="pmid">17241127</pub-id></citation></ref>
<ref id="B82"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname> <given-names>I. M.</given-names></name> <name><surname>Lurie</surname> <given-names>D. I.</given-names></name> <name><surname>Kelley</surname> <given-names>M. W.</given-names></name> <name><surname>Poulsen</surname> <given-names>D. J.</given-names></name></person-group> (<year>2005</year>). <article-title>Adeno-associated virus-mediated gene transfer to hair cells and support cells of the murine cochlea</article-title>. <source>Mol. Ther.</source> <volume>11</volume>, <fpage>843</fpage>&#x02013;<lpage>848</lpage>.<pub-id pub-id-type="doi">10.1016/j.ymthe.2005.06.414</pub-id><pub-id pub-id-type="pmid">15922954</pub-id></citation></ref>
<ref id="B83"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Swanson</surname> <given-names>L. W.</given-names></name></person-group> (<year>1982</year>). <article-title>The projections of the ventral tegmental area and adjacent regions: a combined fluorescent retrograde tracer and immunofluorescence study in the rat</article-title>. <source>Brain Res. Bull.</source> <volume>9</volume>, <fpage>321</fpage>&#x02013;<lpage>353</lpage>.<pub-id pub-id-type="doi">10.1016/0361-9230(82)90145-9</pub-id><pub-id pub-id-type="pmid">6816390</pub-id></citation></ref>
<ref id="B84"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szucs</surname> <given-names>R. P.</given-names></name> <name><surname>Frankel</surname> <given-names>P. S.</given-names></name> <name><surname>McMahon</surname> <given-names>L. R.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>2005</year>). <article-title>Relationship of cocaine-induced c-Fos expression to behaviors and the role of serotonin 5-HT2A receptors in cocaine-induced c-Fos expression</article-title>. <source>Behav. Neurosci.</source> <volume>119</volume>, <fpage>1173</fpage>&#x02013;<lpage>1183</lpage>.<pub-id pub-id-type="doi">10.1037/0735-7044.119.5.1173</pub-id><pub-id pub-id-type="pmid">16300424</pub-id></citation></ref>
<ref id="B85"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname> <given-names>S. L.</given-names></name> <name><surname>Cunningham</surname> <given-names>K. A.</given-names></name></person-group> (<year>1997</year>). <article-title>Serotonergic mechanisms involved in the discriminative stimulus, reinforcing and subjective effects of cocaine</article-title>. <source>Psychopharmacology (Berl.)</source> <volume>130</volume>, <fpage>41</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="doi">10.1007/s002130050210</pub-id><pub-id pub-id-type="pmid">9089847</pub-id></citation></ref>
<ref id="B86"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>White</surname> <given-names>L. A.</given-names></name> <name><surname>Eaton</surname> <given-names>M. J.</given-names></name> <name><surname>Castro</surname> <given-names>M. C.</given-names></name> <name><surname>Klose</surname> <given-names>K. J.</given-names></name> <name><surname>Globus</surname> <given-names>M. Y. T.</given-names></name> <name><surname>Shaw</surname> <given-names>G.</given-names></name> <etal/></person-group> (<year>1994</year>). <article-title>Distinct regulatory pathways control neurofilament expression and neurotransmitter synthesis in immortalized serotonergic neurons</article-title>. <source>J. Neurosci.</source> <volume>14</volume>, <fpage>6744</fpage>&#x02013;<lpage>6753</lpage>.<pub-id pub-id-type="pmid">7965075</pub-id></citation></ref>
<ref id="B87"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>P.</given-names></name> <name><surname>Ye</surname> <given-names>Y.</given-names></name> <name><surname>Svendsen</surname> <given-names>C. N.</given-names></name></person-group> (<year>2002</year>). <article-title>Transduction of human neural progenitor cells using recombinant adeno-associated viral vectors</article-title>. <source>Gene Ther.</source> <volume>9</volume>, <fpage>245</fpage>&#x02013;<lpage>255</lpage>.<pub-id pub-id-type="doi">10.1038/sj.gt.3301646</pub-id><pub-id pub-id-type="pmid">11896463</pub-id></citation></ref>
<ref id="B88"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname> <given-names>X.</given-names></name> <name><surname>Li</surname> <given-names>J.</given-names></name> <name><surname>Samulski</surname> <given-names>R. J.</given-names></name></person-group> (<year>1998</year>). <article-title>Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus</article-title>. <source>J. Virol.</source> <volume>72</volume>, <fpage>2224</fpage>&#x02013;<lpage>2232</lpage>.<pub-id pub-id-type="pmid">9499080</pub-id></citation></ref>
<ref id="B89"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>T.</given-names></name> <name><surname>Pandey</surname> <given-names>S. C.</given-names></name></person-group> (<year>2000</year>). <article-title>Cellular localization of serotonin(2A) (5HT(2A)) receptors in the rat brain</article-title>. <source>Brain Res. Bull.</source> <volume>51</volume>, <fpage>499</fpage>&#x02013;<lpage>505</lpage>.<pub-id pub-id-type="doi">10.1016/S0361-9230(99)00272-5</pub-id><pub-id pub-id-type="pmid">10758340</pub-id></citation></ref>
<ref id="B90"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamaguchi</surname> <given-names>T.</given-names></name> <name><surname>Sheen</surname> <given-names>W.</given-names></name> <name><surname>Morales</surname> <given-names>M.</given-names></name></person-group> (<year>2007</year>). <article-title>Glutamatergic neurons are present in the rat ventral tegmental area</article-title>. <source>Eur. J. Neurosci.</source> <volume>25</volume>, <fpage>106</fpage>&#x02013;<lpage>118</lpage>.<pub-id pub-id-type="doi">10.1111/j.1460-9568.2006.05263.x</pub-id><pub-id pub-id-type="pmid">17241272</pub-id></citation></ref>
<ref id="B91"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zayara</surname> <given-names>A. E.</given-names></name> <name><surname>McIver</surname> <given-names>G.</given-names></name> <name><surname>Valdivia</surname> <given-names>P. N.</given-names></name> <name><surname>Lominac</surname> <given-names>K. D.</given-names></name> <name><surname>McCreary</surname> <given-names>A. C.</given-names></name> <name><surname>Szumlinski</surname> <given-names>K. K.</given-names></name></person-group> (<year>2011</year>). <article-title>Blockade of nucleus accumbens 5-HT2A and 5-HT2C receptors prevents the expression of cocaine-induced behavioral and neurochemical sensitization in rats</article-title>. <source>Psychopharmacology (Berl.)</source> <volume>213</volume>, <fpage>321</fpage>&#x02013;<lpage>335</lpage>.<pub-id pub-id-type="doi">10.1007/s00213-010-1996-3</pub-id><pub-id pub-id-type="pmid">20814782</pub-id></citation></ref>
</ref-list>
</back>
</article>
